MANIPULATIONS OF MACROPHAGE ACTIVATION THROUGH TARGETED DELIVERY OF INTERFERON REGULATORY FACTOR GENES MEDIATED BY RECOMBINANT ADENOVIRUS-CONJUGATED ZYMOSAN by Zhang, Mengmeng
Clemson University
TigerPrints
All Theses Theses
7-2008
MANIPULATIONS OF MACROPHAGE
ACTIVATION THROUGH TARGETED
DELIVERY OF INTERFERON REGULATORY
FACTOR GENES MEDIATED BY
RECOMBINANT ADENOVIRUS-
CONJUGATED ZYMOSAN
Mengmeng Zhang
Clemson University, chrissie0509@gmail.com
Follow this and additional works at: https://tigerprints.clemson.edu/all_theses
Part of the Oncology Commons
This Thesis is brought to you for free and open access by the Theses at TigerPrints. It has been accepted for inclusion in All Theses by an authorized
administrator of TigerPrints. For more information, please contact kokeefe@clemson.edu.
Recommended Citation
Zhang, Mengmeng, "MANIPULATIONS OF MACROPHAGE ACTIVATION THROUGH TARGETED DELIVERY OF
INTERFERON REGULATORY FACTOR GENES MEDIATED BY RECOMBINANT ADENOVIRUS-CONJUGATED
ZYMOSAN" (2008). All Theses. 399.
https://tigerprints.clemson.edu/all_theses/399
i 
 
 
 
 
 
 
 
MANIPULATIONS OF MACROPHAGE ACTIVATION THROUGH TARGETED DELIVERY 
OF INTERFERON REGULATORY FACTOR GENES MEDIATED BY RECOMBINANT 
ADENOVIRUS-CONJUGATED ZYMOSAN 
 
 
A Thesis 
Presented to 
the Graduate School of 
Clemson University 
 
 
In Partial Fulfillment 
of the Requirements for the Degree 
Master of Science 
Biological Sciences  
 
 
by 
Mengmeng Zhang 
August 2008 
 
 
Accepted by: 
Dr. Xianzhong Yu, Committee Chair 
Dr. Thomas Wagner 
Dr. Yanzhang Wei 
 
 
ii 
ABSTRACT 
 
 
According to the different phenotypes and distinct patterns of gene expression, 
macrophages can be subdivided into two types: M1 and M2.  The M1 macrophages, 
which are activated through the classical pathway, have a proinflammatory 
characteristic, providing an in-front defense line against different kinds of pathogens 
as well as malignant cells.  On the other hand, the M2 macrophages are 
immunosuppressive and instead can promote tumor growth and dissemination.  The 
solid tumor tissues are often infiltrated with a large number of macrophages, the 
so-called tumor-associated macrophages (TAMs).  TAMs, which are polarized into 
M2 phenotype under the tumor microenvironment, promote tumor progression by 
favoring angiogenesis, extracellular matrix (ECM) remodeling, and tuning down of 
adaptive immunity.  Although the molecular mechanisms underlying the process of 
macrophage polarization is not fully understood, defective activation of NF-ĸB 
signaling pathway has been frequently observed in TAMs.  Pharmacological skewing 
of TAM polarization from an M2–like phenotype to a full M1 phenotype has been 
shown to sustain antitumor immunity.  In the present study, a novel 
macrophage-targeted, particulate-mediated gene delivery system was designed aiming 
to modulate the activation status of the targeted macrophage cells for cancer therapy.  
Using zymosan particles conjugated with recombinant adenoviruses encoding 
different interferon regulatory factor (IRF) family genes, specifically IRF1, IRF3, and 
IRF7, the current system, taking advantage of the characteristic of phagocytosis of 
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macrophages as well as the capability of adenovirus to escape from the phagosomes,  
achieved virtually 100% transduction efficiency in RAW-Blue macrophage cell line.  
Through reporter assay, cytokine antibody array, and the measurement of NO 
production, our results showed an increased NF-ĸB activity in the cells treated by the 
adenovirus-zymosan conjugates.  In addition, cytokine antibody array analysis also 
revealed increased expressions of many pro-inflammatory cytokines down-stream of 
the NF-ĸB or IRF signaling pathway in treated cells.  This increased expression of 
pro-inflammatory cytokines probably reflects an added effect from three different 
sources: the effect elicited by the binding of zymosan to the TLR2; the effect from the 
cells sensing viral dsDNA through TLR9-dependent and/or –independent pathways; 
and the effects directly from the expression of the transfected IRF genes.  Further 
works are needed to study the effects of the current system in primary mouse 
macrophages, especially to test whether the transfected macrophages have elevated 
activities against tumor cells. 
 
 
Key Words: Tumor-associated Macrophages, Interferon Regulatory Factor, NF-ĸB, 
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CHAPTER ONE 
 
LITERATURE REVIEW 
 
 
1. Tumor-associated macrophages (TAMs) 
1.1. Introduction of TAMs 
From a myriad of histological observations, the infiltration of a large number 
of leukocytes has been considered as a characteristic of tumor tissues.  Macrophages 
in the tumor tissues, the so-called tumor-associated macrophages (TAMs), represent a 
predominant population of mononuclear leukocytes in tumor stroma.  Thus, in the 
study of tumor development and progression, an increasing interest has been focused 
on the functions of tumor infiltrating leukocytes, especially the TAMs. 
While a few tumors may grow as cell suspensions, for example leukemia and 
ascites tumor, most tumors form into solid masses of tissues mainly composed of 
malignant cells and stroma, which are two interdependent components of tumors and 
function reciprocally.  The tumor stroma which is largely produced from normal host 
tissue includes matrix components, blood vessels as well as inflammatory cells. 
Malignant cells may alter the properties their stroma by cell-to-cell contact, soluble 
factors and/or by modification of the extra-cellular matrix (ECM) in support of their 
growth.  On the other hand, in response to malignant cells, the stromal cells are able 
to modify the phenotypes, invasiveness and metastatic capacity of tumor cells, 
typically promoting their progression.  A vast diversity of molecules are produced by 
different cellular components within the complex tumor microenvironment such as 
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cytokines, chemokines, growth factors and proteases, which may positively or 
negatively influence tumor survival and growth. 
TAMs, as an important component of stroma, are originated from peripheral 
blood monocytes in the blood circulation which are recruited into the tumor mass by 
tumor-derived chemoattractants and then differentiated into tissue macrophages.  
Originally, it was assumed that TAMs were a principal part of host defence against 
developing tumors based on some early observations and the well-known important 
roles of macrophages in the immune system (Knowles and Harris, 2007).  Although 
the mechanisms by which TAMs interact with tumor cells are not fully understood, 
recent works have suggested a very complicated role macrophages play in tumor 
development and progression.  First of all, a number of observations showed that 
TAMs may be involved in the inhibition of tumor growth.  By comparing the 
cytotoxic activity of peritoneal macrophages (PMs) and peripheral blood monocytes 
(PBMs) after in vitro activation with interferon-γ (IFN-γ) and lipopolysaccharide 
(LPS), Wilbanks et al. suggested that PMs from ovarian cancer patients were 
significantly more cytotoxic than those from non-activated controls (Wilbanks et al., 
1999).  In line with this result, another observation showed that the infiltration of 
tumor-associated macrophages is inversely correlated with tumor progression in 
human prostate cancer (Shimura et al., 2000).  Additionally, the TAMs have been 
identified to be able to orchestrate the production of various substances, such as IFNs, 
platelet factor-4, angiostatin and thrombospondins, which mediate the suppression of 
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tumor growth and metastasis through negatively regulating angiogenesis 
(Sunderkotter et al., 1994) (O'Reilly et al., 1994).  It was also speculated that, 
through the collaboration with T-helper cells, the macrophages may present 
tumor-associated antigens to induce an antitumor immune response.  Because of 
their potential tumoricidal capabilities, TAMs have gained a lot of interests in the 
development of novel macrophage-based antitumor therapies.  
Despite these works that seem to lead to a conclusion that macrophages, if 
appropriately activated, can prevent the establishment and proliferation of tumors, it 
was observed as early as the 1980s that, macrophages may also support tumor growth 
and dissemination (Steele et al., 1984).  Currently, there is an increasing consensus 
on their pro-tumor role based on more and more research works on TAMs.  The 
ambivalent relationship between macrophages and tumor cells suggests that the 
tumor-associated macrophages have a high plasticity, and can function differently in 
response to different signals within the tumor microenvironment. (Sica et al., 2007)  
1.2. Macrophage classification and the heterogeneity of TAM phenotypes 
According to the different phenotypes and distinct patterns of gene expression, 
macrophages can be subdivided into type I and type II macrophages (Figure 1-1).  
The type I macrophages (M1) have a phenotypic pattern of high interleukin-12 
(IL-12), low IL-10, or low IL-4/-13.  The propensity of M1 is often increased in 
response to opsonized ligands and toll-like receptor (TLR) engagement.  Generally, 
the typical type I macrophages play an indispensable role in both innate and acquired 
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immunity, and therefore they have a proinflammatory characteristic.  They provide 
an in-front defense line against different kinds of pathogens and malignant cells via 
phagocytosis and/or induction of antibody-dependent cellular cytotoxicity.  
Activated macrophages have the capability to recognize and bind to tumorigenic cells, 
a process that lead to the subsequent lysis or phagocytosis of tumor cells.  As an 
example, studies have showed that the amount of phosphatidylserine located in the 
outer membrane leaflets is different between normal cells and tumor cells, and 
macrophages can distinguish the differences thus recognize the tumor cells (Utsugi et 
al., 1991) (Elnemr et al., 2000). 
 
Figure 1-1.  Polarization of macrophages. 
However, the type II macrophages, or shortly M2, which have the 
IL-10+/IL-12- phenotype, have an immunosuppressive characteristic.  Evidence 
showed that TAMs can express typical M2 markers and have defective expression of 
some proinflammatory cytokines, such as IL-12, tumor necrosis factor-alpha (TNF-α), 
CC chemokine ligand 3 (CCL3), and IL-1 (Biswas et al., 2006) but high expression of 
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IL-10 (Sica et al., 2000), hence the TAMs can be skewed to be M2.   
IL-12, typically produced by macrophages, is a very important cytokine in 
immune resistance against pathogens.  IL-12 is known as a T cell stimulating factor, 
which can stimulate the growth and function of T cells.  It can also facilitate the 
production of IFN-γ and TNF-α and alleviate IL-4-mediated suppression of IFN-γ.  
Therefore, lack of IL-12 production may result in dysfunction of macrophages’ 
antitumor responses.  It was observed that the expression of IL-12 gene is partially 
controlled by members of nuclear factor-kappa B (NF-κB) family and failure to 
produce IL-12 may be associated with defective activation of p50/p65 NF-κB in 
TAMs (Sica et al., 2000).  This defective activation of NF-κB in TAMs also 
correlates with impaired expression of NF-κB-dependent inflammatory functions, for 
example, the expression of TNF-α, IL-1 and other cytotoxic mediators.  Moreover, 
Ibe et al. proposed that high level production of IL-10 triggered by CCL2 or other 
tumor-derived chemotactic factors (TDCFs) plays an important role in defective IL-12 
production.  By interrupting the communication between tumor cells and their 
stroma, TAMs could be switched towards IFN-γ production and tumor rejection (Ibe 
et al., 2001).  Their observations also indicate that therapeutics targeted to block the 
production of IL-10 as well as other immunosuppressive cytokines in tumor sites may 
restore the antitumor functions of TAMs.  
Interestingly, although TAMs have phenotypes similar to that of the 
alternatively activated M2 macrophages, the properties of TAMs are intermediate 
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between those of proinflammatory (M1-like) and immunosuppressive (M2-like) 
macrophages and more M2-polarized.  For example, TAMs can express high levels 
of both M1 marker like nitric oxide synthase-2 (NOS2) and M2 marker like 
arginase-1 (ARG1) simultaneously (Sica and Bronte, 2007).  The expression of 
NOS2 and/or ARG1 can promote several metabolic reactions responsible for the 
dysfunction of T cell responses, including the depletion of extracellular L-Arg, the 
release of NO as well as increased production of reactive oxygen and nitrogen species.  
Moreover, TAMs from murine fibrosarcoma, which usually show the M2-orientied 
phenotypes, also express proinflammatory chemokines such as CXC chemokine 
ligand 9 and 10 (CXCL9 and CXCL10), and CCL5 (Biswas et al., 2006).  It was 
proposed in a dynamic model recently that during the tumor growth, there is a 
dynamic change in the tumor microenvironment which could result in a gradually 
switching of macrophage polarization, from M1 in the tumor initiation to M2 in the 
established tumors (Sica et al., 2008).  The functions of TAMs are controlled within 
a functional spectrum with M1 and M2 being the two extremes.  Therefore, it is not 
surprising that the TAMs are in between M1 and M2.   
1.3. Macrophage polarization and M2-polarized TAMs 
In response to different intercellular signals, macrophages can be polarized 
into different phenotypes.  Recent works reviewed by Sica et al. (Sica et al., 2007)  
suggested that the type I macrophages which have the antitumor activity are 
differentiated from monocytes exposed to certain factors such as 
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granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN-γ, LPS and some 
bacterial products; whereas macrophage colony-stimulating factor (M-CSF), 
IL-4/-13/-10 and some immunosuppressive agents trigger macrophages to 
differentiate toward type II macrophages (Figure 1-2).  Among the factors that 
induce the antitumor activity of macrophages, the IFN family, particularly IFN-γ, is 
the most important one.  Despite the lack of detailed knowledge of mechanisms by 
which IFN mediate tumoricidal functions of macrophages, lots of in vitro, in vivo and 
clinical studies have provided evidence to support the notion that IFN-inducible type I 
macrophages have significant antitumor activity. 
 
Figure 1-2.  Cancer-induced polarization of macrophages. 
An in vitro study showed that treatment of monocytes with IFN-γ alone or in 
combination with TNF-α, GM-CSF or PPD, before/after co-cultured with tumor 
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(HPC-4) cells, remarkably enhanced the de novo production of molecular factors 
related to antitumor activity of macrophages (Baj-Krzyworzeka et al., 2004).  It has 
also been reported that gene transfer of IFN-γ using adenoviral vector had negative 
effects on tumor growth.  Urosevic et al. transferred the IFN-γ gene into 19 patients 
with cutaneous lymphomas through injection of adenovirus-mediated IFN-γ 
(Ad-IFN-γ) and performed transcriptional profiling on skin lesions obtained from the 
patients before and after the treatment.  The gene expression profiles revealed a 
distinct gene expression signature in the lesions treated with Ad-IFN-γ.  The 
productions of IFN-γ- and many of both type I IFN- and type II IFN- inducible genes 
were detected in the lesions after treatment with Ad-IFN-γ (Urosevic et al., 2007).  
The specific signaling mechanisms that may regulate macrophage polarization 
have been partially identified.  One of them is the NF-κB-mediated signal 
transduction.  The activation of NF-κB turns on the inflammatory repertoire of 
macrophages, leading to the expression of proinflammatory cytokines (Karin and 
Greten, 2005).  Defective NF-κB activation could inhibit the transcription of some 
key cytokines related to M1 phenotypes and the production of cytotoxic mediators.  
For example, the impaired expression of NF-κB-induced inflammatory factors, such 
as NO, TNF-α, IL-1, and IL-12, were observed in the TAMs isolated from tumors in 
advanced stages (Sica et al., 2000).  Studies have also indicated that NF-κB is 
activated in TAMs during the early stages of tumor initiation, but is largely suppressed 
in established tumors (Saccani et al., 2006).  As an important upstream component of 
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NF-κB activation, TLR/IL-1R signaling also plays a pivotal role in regulating 
macrophage polarization (Karin et al., 2006).  Additionally, the Tie-2/Ang-2 pathway, 
the TRIF/TBK1/IRF3 pathway, and hypoxia-induced pathway are reported to be 
possible pathways in regulating the “shift” in macrophage phenotypes (Biswas et al., 
2008).  As more evidences emerge revealing the nature of the signaling in the 
establishment of M2-like phenotypes of TAMs, the more and higher possibilities we 
have to find the targets to reprogram them to express antitumor activities.  
1.4. TAMs in the tumor microenvironment 
TAMs are ‘educated’ into M2-like phenotypes by tumor-derived factors, such 
as cytokines, growth factors, chemotactic molecules and proteases which may either 
up-regulate or down-regulate the expression of macrophage effector molecules, thus 
influence the functions of macrophages.  Although it has been reported in many 
studies that macrophages can promote tumor cytotoxicity and stimulate antitumor 
lymphocytes by secreting a variety of molecular factors such as cytokines, their 
cytotoxic activities may be largely suppressed in the tumor microenvironment.  
Many tumor-derived molecules which can deactivate or suppress the cytotoxic 
activity of activated TAMs, including IL-4, IL-6, IL-10, macrophage-derived 
chemotactic factor (MDF), transforming growth factor beta1 (TGF-β1), prostaglandin 
E2 (PGE2), and M-CSF, have been identified (Elgert et al., 1998). 
As more and more studies related to TAMs unveiled their paradoxical roles 
and functions on tumor cells, it is becoming obvious that multiple molecules play a 
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pivotal role in the cross-talk between cancer cells and TAMs.  By transplanting 
tumors into hosts with defective T cells or natural killer (NK) cells, Mantovani et al. 
found that in many neoplasms the extent of macrophage infiltration and the number of 
macrophages in tumor tissues are not mainly determined by specific immunity but by 
the factors derived from cancer cells.  The key players in the regulation of 
macrophage infiltration have been pointed to be monocyte chemotactic protein-1 
(MCP-1/CCL2) and related CC chemokines (Nesbit et al., 2001).  
In addition, another study has demonstrated that TAMs accumulation in 
primary tumors is significantly correlated with the level of CCL2 expression and 
tumor-derived chemotactic factors were found expressed by murine and human tumor 
cells (Hoshino et al., 1995).  It has also been demonstrated that low level MCP-1 
secretion led to tumor formation, while high level secretion resulted in marked tumor 
necrosis with massive macrophage infiltration.  To date, CCL2 has been shown to be 
produced by a variety of human tumors, such as melanoma, malignant glioma, 
ovarian cancer and meningioma.  MCP-2 and MCP-3, also known as CCL8 and 
CCL7, are the other two members of the CCL2 family which were isolated from 
tumor cell lines.  In addition, breast carcinoma at advanced stage was reported to be 
associated with increased expression of CCL5, and CCL5 receptor (CCR5) was 
detected on TAMs.  It was suggested that CCL5 may play a role in macrophage 
migration, tumor progression, and protumorigenic activity (Azenshtein et al., 2002). 
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1.5. TAMs and angiogenesis 
The early stage of tumor development is to induce blood vessel growth 
(angiogenesis) by tumor cells, a fundamental step in the transition of tumors from a 
dormant state to a malignant state.  Angiogenesis is considered to be the main 
mechanism by which solid tumors can obtain nutrition supply for their proliferation 
and metastasis.  
TAMs are thought to be very important in several processes related to tumor 
angiogenesis such as inflammation and tissue remodeling.  They can secret a vast 
diversity of factors that promote angiogenesis including vascular endothelial growth 
factor (VEGF), granulocyte colony-stimulating factor (GCSF), basic fibroblasts 
growth factor (bFGF), insulin-like growth factor-I (IGF-I), platelet derived growth 
factor (PDGF), transforming growth factor-β (TGF-β), tumor necrosis factor-α 
(TNF-α), IL-1, IL-6, IL-8, substance P, prostaglandins and other kinds of monokines.  
Experimental data demonstrated that neoplastic tissues showed angiogenic activity 
only when macrophages were present (Mostafa et al., 1980).  
A study based on flow cytometry analysis provided some evidence for the 
relationship between tumor angiogenesis and macrophages.  By identifying and 
quantifying the composition of infiltrating leukocytes in medullary and ductal breast 
tumor tissues, the researchers showed that infiltrating leukocytes (macrophages in 
particular) in medullary carcinoma are 3.2-fold more than those in ductal carcinoma.  
This higher infiltration of macrophages was thought to be correlated with 3-fold 
12 
enhanced endothelial expression of intercellular adhesion molecule-1 (ICAM-1), the 
most important adhesion molecule for leukocyte extravasation (Reiss et al., 1998) in 
medullary carcinoma (Bouma-ter Steege et al., 2004).  Simultaneously, a noticeable 
overexpression of both VEGF-C and VEGF-D in ductal carcinomas was found.  
From those observations, the authors suggested that the enhanced expression of 
angiogenic factors in ductal carcinoma endothelial cells is responsible for the 
suppression of ICAM-1 which in turn possibly down-regulate the levels of 
macrophage infiltration. 
Proteolytic enzymes, especially matrix metalloproteinases (MMPs), are also 
key molecular factors in angiogenesis and mainly secreted by TAMs.  Although the 
mechanisms by which MMPs secreted by TAMs enhance angiogenesis are not 
completely understood, some key players have been identified.  During tumor 
angiogenesis, tumor extracellular matrix is digested by MMPs to support rapid tumor 
growth, invasion, and metastasis.  It is also reported that by mediating the 
degradation of type IV collagen, MMP-9 can promote the migration and invasion of 
both tumor cells and macrophages since tumor xenografts in MMP-9 knock-out mice 
were smaller and contained fewer TAMs than wild-type counterparts (Huang et al., 
2002). 
Up till now, different types of synthetic inhibitors against MMPs (MMPIs) 
have been developed and put into clinical trials as anti-cancer therapeutics, but the 
results of clinical trials turned out to be not very encouraging.  However, this does 
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not diminish the importance of MMPs in the process of normal cell transformation to 
malignant cells.  Details about MMPs, specifically when and how they take part in 
the development of cancers are needed for more advanced application of MMPIs. 
Moreover, TNF-α is largely produced by TAMs and is also a 
hypoxia-inducible pro-angiogenic cytokines.  TNF-α can initiate a cascade of signal 
transductions upon its secretion, leading to the production of other factors which in 
turn function positively on angiogenesis as well as other essential processes during 
tumor development.  A TNF-α-dependent pathway to induce the expressions of 
MMP-2 and MMP-9 in TAMs has been demonstrated recently.  Also, an increased 
production of TNF-α was observed when macrophages were co-cultured with cancer 
cells (Hagemann T., 2004).  Additionally, data from CSF-1 knock-out mice and 
CSF-1 knock-down with antisence or RNAi all showed a reduced expression of 
MMPs and VEGF.  When CSF-1 was re-introduced into the experimental system, 
increased TAMs and accelerated tumor progression and metastasis were observed (Lin 
et al., 2001). 
TAMs may also have negative effects on tumor angiogenesis through the 
production of factors such as thrombospondin 1 (TSP1) and GM-CSF.  These factors 
in turn stimulate the production of the angiogenic protein plasminogen activator 
inhibitor type 2 (PAI-2). 
1.6. TAMs and hypoxia 
Another phenomenon observed in tumor tissue is that TAMs are often found in 
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the regions with low oxygen tension.  Hypoxia, a term used to describe the low 
oxygen conditions (an oxygen tension of 0.1%-0.5%), usually occurs more than 
100μm from blood vessels in tumor microenvironment.  Besides being regulated by 
cytokines, the localization of TAMs is also, likely to a large extent, regulated by 
hypoxia. 
Hypoxic conditions in tumor tissues can induce the expression of all three 
endothelial cell adhesion molecules necessary for monocytes extravasation, among 
which VEGF is the important hypoxia-induced genes and is also the most extensively 
studied.  The VEGF-R1/flt-1 on monocytes can be activated by binding of VEGF.  
A positive correlation between elevated VEGF expression and increased macrophage 
infiltration has been observed in breast cancer (Leek et al., 2000).  In addition to its 
chemoattractic activity on macrophages, VEGF also has a pro-angiogenic activity.  
The expression of VEGF is induced by hypoxia via the expression of 
hypoxia-inducible factor-1 alpha (HIF-1α).  CXCR4, a receptor for CXC chemokine 
SDF-1/CXCL12, is also evidenced to be up-regulated in macrophages by hypoxia 
through HIF-dependent pathway (Schioppa et al., 2003).  A possible alternative 
mechanism for recruiting macrophages to the hypoxic areas in tumors was proposed 
based on the observation that macrophages accumulated in the regions where 
endothelial monocyte activating peptide II (EMAP II) was highly expressed. 
Surprisingly, some factors involved in macrophage migration such as CCR5 
are down-regulated by hypoxia, as mentioned above.  Therefore, it is suggested that 
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hypoxia can, on one hand, induce the expression of chemoattractants which are 
responsible for macrophage localization in hypoxic regions; on the other hand, it can 
inhibit other molecular factors that may attract macrophages/monocytes randomly 
into tumor sites.   In line with this assumption, Grimshaw et al. found that hypoxic 
macrophages can up-regulate the expression of mitogen-activated protein kinase 
(MAPK) phosphatase-1 (MKP-1), an enzyme that can dephosphorylate ERK1/2 and 
p38 MAPK, thus hypoxia indirectly inhibits MCP-1-induced macrophage migration 
which requires the phosphorylation of p38 MAPK and ERK1/2 (Grimshaw and 
Balkwill, 2001). 
Hypoxia-inducible factor is a heterodimeric transcription factor that can 
initiate the expression of a broad range of genes involved in angiogenesis, cell cycle 
control as well as apoptosis.  Fully activated HIF factor contains both of its two 
subunits: one is alpha subunit which can be degraded by oxygen-requiring enzymes 
under normal oxygen condition and the other is a constitutively expressed beta 
subunit.  Hypoxia results in the accumulation of HIF alpha subunit, allowing its 
activation of downstream genes.  An in vivo study provided the evidence that tumor 
xenografts produced from HIF-1α-/- embryonic stem cells and HIF-1β-deficient 
fibroblasts had poor vascularization and reduced rate of growth in nude mice 
compared with the wide-type counterparts (Maxwell et al., 1997). 
Some key effector molecules in angiogenesis secreted by TAMs are also 
regulated by hypoxia.  MMP-1 and MMP-7 are hypoxia-inducible MMPs secreted 
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by TAMs, and MMP-1 has been identified as being regulated by HIF-2α (Petrella et 
al., 2005).  TAMs, angiogenesis, and hypoxia are highly related and are essential for 
tumor growth and expansion. 
1.7. Conclusion of TAMs 
Differentiated mature TAMs are similar to M2 macrophages both 
phenotypically and functionally.  TAMs, which preferentially express M2-associated 
genes, promote tumor progression by secreting cytokines that promote tumor growth, 
favoring angiogenesis and/or lymphenogenesis, favoring tumor-induced ECM 
remodeling, and tuning of adaptive immunity.  However, they can also express genes 
associated with classical M1 macrophages such as IFN-inducible M1 chemokines: 
CXCL9, CXCL10 and CXCL6.  IFN-inducible chemokines generally have 
potentially antitumor activities, as many of such chemokines are inhibitors of 
angiogenesis and chemoattractant of cytotoxic T cells.  As a unique cell population 
within tumor microenvironment, the cytotoxic activities of TAMs are often 
suppressed and susceptibility to IFN-γ/LPS mediated stimulation is reduced.  The 
mechanisms behind the paradoxical effects of TAMs on tumors have been extensively 
studied and some clues have gradually emerged. 
The cross-talk between cancer cells and macrophages which can influence 
TAM phenotypes is very important during tumor development.  The mechanisms 
governing the interaction between macrophages and tumor cells are extensively 
studied.  One of the mechanisms proposed was that immunosuppressive activities of 
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tumor might be regulated by overexpression of those immunosuppressive factors.  
The major contributors identified by far are PEG2, M-CSF, TGF-β1, IL-4, IL-6 as 
well as IL-10.   
2. Interferons (IFNs) 
2.1. Introduction of IFNs 
It has been fifty years since the first description of interferon by Alick Isaacs 
and Jean Lindemann.  In their landmark study, they found that a factor, named 
“interferon” by them thereafter, was released following incubation of heated virus 
with chick chorioallantoic egg membranes; and this factor can inhibit viral replication 
in infected cells.  Since then, different viral-induced IFNs have been discovered and 
their antiviral activities have been studied.  In 1969, Gresser et al. reported that 
tumor growth was inhibited in animals after treatment with IFN (Gresser et al., 1969).  
However, the IFN preparations used in those studies were not pure so that the 
discoveries with regard to the antitumor properties of IFNs were not completely 
convincing.  It was not until 1980 when cloning of IFNs became a possibility that the 
research on IFNs entered into a new era and has made a great progress (Taniguchi et 
al., 1980).  
2.2. Classification of IFNs 
Various pathogen-associated molecules, such as bacterial LPS, unmethylated 
CpG DNA, and viral double-stranded RNAs, can elicit a series of reactions leading to 
innate immune response in host.  These reactions result in the production of various 
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cytokines such as IFN-α and IFN-β, which belong to type I IFNs and are vital 
cytokines in the operation of adaptive immunity.  Besides the two key cytokines 
IFN-α and IFN-β that are most extensively studied, type I IFNs also include IFN-ω, 
IFN-ε and IFN-κ.  All of the members in type I IFN family can bind to a specific cell 
surface receptor, the IFN-α receptor (IFNAR), in both autocrine and paracrine 
manners to exert multiple biological functions including the activation of antiviral 
defense, modulation of the immune system, and host defense against tumors.  In the 
human genome, type I IFN family contains three subtype genes: thirteen IFN-α genes, 
one IFN-β gene and two IFN-ε genes. 
There are other two major classes of IFNs, type II IFNs and type III IFNs 
based on sequences, chromosomal locations, and receptor specificities. 
The only member of human type II interferon is IFN-γ, a dimeric soluble 
cytokine originally called macrophage-activating factor.  Unlike type I IFNs which 
are induced by viruses, the production of type II IFNs, mostly by lymphocytes, is 
stimulated by different immune stimuli, such as mitogens, antilymphocytic serum and 
antigens.  IFN-γ initiates the signal transductions through a different receptor 
composed of IFNGR-1 and IFNGR-2 subunits.  The single copy of IFN-γ gene is 
located on chromosome 12.   
The newly discovered human type III IFNs encoded by genes on chromosome 
19 consist of three members: IFN-λ1, IFN-λ2 and IFN-λ3, also known as IL-29, 
IL-28A and IL-28B, respectively (Kotenko et al., 2003).  Structural and functional 
19 
characterization of the IFN-λ1 and IFN-λ3 gene promoters revealed their similarities 
to IFN-β and IFN-α genes, respectively. 
A recent study has shown that both antiviral type I and type III IFN genes can 
be activated by viral infection/replication via TLR-dependent and -independent 
pathways (Sheppard et al., 2003), but type III IFNs bind to a distinct membrane 
receptor composed of IFNLR1 and IL10R2.  Notably, the IFNLR1 is specific to type 
III IFNs, whereas the IL10R2 subunit can also interact with IL-10, IL-22 and IL-26. 
Despite their diverse structural and functional properties, the three classes of 
IFNs have several effects in common, such as (1) they have antiviral and 
antioncogenic properties; and (2) they can activate macrophages and NK cells to 
present foreign epitopes to T cells. 
2.3. IFN functions 
IFNs are central regulatory mediators of the immune system.  They can be 
produced by different types of immune cells in response to a wide range of foreign 
agents, such as viruses, parasites, and tumor cells.  Major activities of IFNs include 
immunomodulating activities, antiviral effects, and antitumor activities.  At the 
molecular level, IFNs exert their modulatory functions through many mechanisms 
such as (1) activation of macrophages and other lymphocytes, and (2) enhancement of 
the expressions of major histocompatibility complex (MHC) class I and II antigens 
and tumor-associated surface antigens, thus increasing the presentation of peptides to 
T cells.  
20 
As an extraordinarily well studied case among various functions of IFNs, 
nearly all types of IFNs are important in fighting against RNA virus infection.  IFNs 
act on target cells to establish an antiviral state in the cells which has influences on 
various phases of viral infection, including virus entry, transcription, RNA stability, 
translation, maturation, assembly as well as release.  One of the mechanisms by 
which dsRNA-induced IFNs fight against viruses has been well established.  RNase 
L is an IFN-inducible ribonuclease which, upon activation, destroys all RNA within 
the cell.  The type I IFNs induced by viral RNA stimulate the expression of 
2’-5’-linked oligoadenylate by activating an enzyme called 2’-5’ oligoadenylate 
synthetase, which in turn can activate RNase L to degrade viral RNA as well as 
cellular RNA.  Interestedly, this IFN-inducible enzyme, RNase L, has also been 
reported to be associated with prostate cancer.  For example, one of the studies 
showed that RNASEL gene (the gene that encodes RNase L) mutations and some 
variants allow tumor cells to escape a potent apoptotic pathway (Xiang et al., 2003), 
which supports the possible tumor suppressor role of RNase L as well as IFNs.  This 
study also provided the possibility that there is a link between IFN-induced antiviral 
immunity and antitumor activities. 
Indeed, the antitumor activity of IFNs, manifested on their inhibition of 
malignant cell growth, has long been documented (Sen and Lengyel, 1992).  Studies 
showed that both type I and type II IFNs can induce the expression of the 
promyelocytic leukemia (PML) gene (Heuser et al., 1998), which is involved in 
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haematopoietic differentiation and in the control of cell growth and tumorigenesis 
presumably by encoding a putative tumor suppressor protein involved in the control of 
apoptosis (Rego et al., 2001).   
Particularly, because of their essential role in the induction of apoptosis in 
cancer cells,  IFN-α and IFN-β (IFN-α/β) are sometimes referred to as ‘negative 
growth factors’ (Pestka et al., 1987) (Gresser and Belardelli, 2002).  However, the 
molecular mechanism of their tumor suppression activity is still unknown.  Recently, 
it was reported that there is a link between IFN-α/β signaling and the responses of 
tumor suppressor p53.  It is well known that p53 can induce cell cycle arrest or 
apoptosis once it is activated in response to DNA damage, playing a central role in 
tumor suppression (Vousden and Lu, 2002).  The study carried out by Takaoka et al. 
showed IFN-α/β can induce the transcription of p53 gene, as shown by an increase in 
the level of p53 protein which contributes to tumor suppression (Takaoka et al., 2003). 
Besides direct actions on malignant cells, the IFNs can also stimulate 
immune-mediated antitumor activity through mediator cells.  IFN-γ, originally 
known as the macrophage-activating factor, orchestrates a variety of cellular programs 
in the macrophages through transcriptional regulation of immunologically relevant 
genes.  Macrophages stimulated by IFN-γ induce direct antimicrobial and/or 
antitumor activity with enhanced antigen processing and presentation capacities.  It 
is also highly possible that IFN-γ, both directly and indirectly, initiates a cascade of 
signaling involved in the production of other types of IFNs and IFN-inducible genes, 
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priming the macrophages’ antitumor activity (Schroder et al., 2004).   
As potential antitumor drugs, IFNs have been tested in many clinical trials. 
IFN-α has already been approved to be used in the treatment of hairy cell leukemia in 
1985.  Recombinant IFNs were found to have therapeutic potentials in other 
malignancies, such as chronic myelogenous leukemia (CML), B and T cell 
lymphomas, melanomas, and Kaposi’s sarcoma (Borden, 2005). 
3. Interferon regulatory factors (IRFs) 
3.1. Introduction of IRFs 
Studies on mechanisms of IFNs induction by viruses and dsRNA led to the 
discovery of a family of transcription factors involved in the regulation of IFN genes, 
termed interferon regulatory factors (IRFs).  Actually, the expression of IFN genes is 
primarily regulated at the transcription level which made the IRF family of 
transcription factors the focus of researches.  
The IRF family is a group of transcription factors that play very important 
roles in regulating the expressions of IFN genes as well as IFN-inducible genes (also 
known as IFN-stimulated genes, ISGs).  From the induction of IFNs to diverse IFN 
responses, the IRF family is a focal point of the entire IFN system.  They are also 
involved in the establishment and execution of innate and adaptive immunity, 
modulating the development of the immune system.  Furthermore, they can regulate 
the growth and/or differentiation of many cell types, and accordingly play a pivotal 
role in leukemia and other cancers.   
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To date, the IRF family includes nine members (IRF-1 to IRF-9), all of which 
can bind to IFN-stimulated response element (ISRE) (Taniguchi et al., 2001). 
Generally, the IRF family members have significant homology in the 
N-terminal 115 amino acids which contains a DNA binding domain (DBD).  This 
DBD is featured by having a unique “tryptophan cluster” DNA-binding region of five 
tryptophan residues, which has an α/β architecture consisting of a cluster of three 
α-helices (Helix 1, Helix 2 and Helix 3) flanked by a four-stranded β-sheet on one 
side (Figure 1-3) (Escalante et al., 1998).  The IRF molecules may bind DNA either 
as a monomer or a dimmer depending on their subtypes.  The protein monomer 
binds DNA with a helix-turn-helix (HTH) motif in which three of the five conserved 
tryptophan residues are in contact with DNA.  The HTH motif is composed of Helix 
2 and Helix 3 of the three α-helices in the DNA-binding region with the Helix 3 lying 
in the DNA major grove.  A ‘GAAA’ core sequence within a 13bp DNA element in 
the IFN promoter, known as ISRE, contacts with Helix 3 of the HTH motif.  There is 
another important regulatory domain on the C-termini of IRFs: IRF association 
domain (IAD) which is conserved in all IRFs from IRF-3 to IRF-9 but not in IRF-1 
and IRF-2.  Structural analyses of the C-terminal regulatory region on IRF-4 and 
IRF-8 revealed that the C-terminal IAD is composed of a β-sandwich core flanked by 
helices and loops.  The IAD crystal structure also demonstrated that the 
auto-inhibitory mechanism for IRF-3 and IRF-7 is due to an interaction between H1 
and H5 helices prior to stimulation.  
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Figure 1-3.  Crystal structure of DBD of IRF1.  Helix 1, Helix 2 and Helix 3 are 
shown in blue, green and orange, respectively.  ‘GAAA’ core sequence as well as 
pairing ‘TTTC’ are shown in cyan, whereas the remainder of DNA is shown in purple. 
Three conserved tryptophans that make contacts with DNA are shown.  (PDB 
ID:1IF1) 
It is often observed that IFNs exert their functions in concert with other 
transcription regulators such as NF-κB.  As early as 1989, the NF-κB was identified 
as a critical transcription factor involved in the IFN-β genes regulation (Lenardo et al., 
1989).  Actually, the stimulation of the transcription of IFN-β genes by viruses or 
dsRNA is modulated by an enhanceosome composed of IRFs, NF-κB, activating 
transcription factor (Maxwell et al., 1997)-2 and c-Jun heterodimer, and the high 
mobility group protein HMG I(Y).  The enhanceosome can further bind with histone 
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acetyl transferases and the CREB binding protein (CBP) (Kim and Maniatis, 1997).  
The assembly of IFN-β enhanceosome is a prerequisite for efficient transcription of 
IFN-β genes (Kim et al., 1998).  However, the ISREs of IFN-α gene promoters do 
not contain any NF-κB site, but have multiple 'AANNGAAA' repeats which can be 
bound by members of IRF family.  For example, IRF-1, IRF-3 and IRF-7 together 
with histone transacetylases can form the transcriptionally active IFN-α gene 
enhanceosome (Au et al., 2001).  Therefore, IRFs are very important and required 
for transcriptional activity of type I IFN genes.   
3.2. Regulations of IRF activities 
IRF activities are modulated by a variety of post-translational modifications 
such as phosphorylation, acetylation, ubiquitination, and proteasome-dependent 
degradation.  In the induction of type I IFNs, phosphorylation is the main event to 
regulate the signaling pathways.  It has been discovered that IFN responses depend 
on kinases of the Janus kinase (JAK) and mitogen-activated protein kinase (MAPK) 
families that phosphorylate signal transducers and activators of transcription (STAT) 
proteins (Platanias, 2005).  But the phosphorylation of IRFs is more likely to be 
modulated by other kinases.  For example, the phosphorylation of IRF-3 and IRF-7 
by TBK-1 and IKKε is a prerequisite of IFN induction in the TLR-mediated pathway 
(Solis et al., 2006).  However, it has not been fully explored if phosphorylation is a 
necessary step for IRF activation and translocation. 
Acetylation of IRFs in vivo and in vitro can cause an alteration of DNA 
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binding and transcriptional activities.  For example, IRF-2 and IRF-7 can be 
acetylated by histone acetylases GCN/PCAF and CBP/p300 at the lysine residues 
flanking tryptophan in the DBD.  Although both residues are conserved throughout 
the IRF family, not all IRF family members are acetylated in similar conditions, 
suggesting that the acetylation of IRFs is selective.  
IRFs are degraded by proteasome through the ubiquitin pathway.  It has 
already been found that some viral proteins can degrade IRF-3 and IRF-7 to impair 
the induction of IFNs.  As a matter of fact, the destabilization of IRFs is a normal 
process in regulating IRFs activities.  Saitoh et al. demonstrated that upon interaction 
with the peptidylprolyl isomerase Pin1, IRF-3 changes the isomerization status which 
leads to a rapid destabilization of IRF-3.  Poly-ubiquitination of IRFs linked through 
lysine 48 of ubiquitin is a common mark for IRF degradation.  Strikingly, it was 
shown that mono-, multi- or poly-ubiquitination through lysine 63 rather than lysine 
48 of ubiquitin can enhance transcription-initiating activities IRFs.  One study 
showed that ubiquitination of IRF-7 upon TLR stimulation through an E3 ubiquitin 
ligase, TNF receptor-associated factor 6 (TRAF-6), resulted in increased IFN gene 
transcription (Kawai et al., 2004). 
3.3. IRF-1 
IRF-1, identified in 1988 in Taniguchi’s lab, is the founding member of the 
IRF family and is also the one most extensively studied at the molecular level.  It 
was isolated as a DNA-binding protein due to its affinity to a specific DNA sequence, 
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termed positive regulatory domain I (PRDI) element, in the IFN-β promoter 
(Miyamoto et al., 1988).  The IRF-1 protein is constitutively expressed and is 
localized in the nucleus.  It has two consensus nuclear localization signals (NLS) to 
mediate its nuclear translocation.  Between amino acid 185 and 256 on IRF-1 
molecule, there are two transcription activator fragments which are enhanced by a 
C-terminal fragment that does not have activator function per se.  The N-terminal 
contains a 60 amino acids domain which can strongly inhibit the transcriptional 
activity of IRF-1.  This repression domain exits in most, if not all, of the members of 
IRF family identified so far. 
IRF-1 mRNA is expressed at a basal level in nearly all the cell types examined 
except early embryonic cells (Kroger et al., 2002).  Transcription of IRF-1 mRNA 
can be induced by many factors including IFNs, dsRNA, certain cytokines and some 
hormones.  Among those inducers, IFN-γ is the strongest one known by far.  
Additionally, certain combinations, for example IFN-γ and TNF-α, can elicit even 
higher level of IRF-1 mRNA expression.  On the other hand, some molecular factors, 
such as IL-4, can inhibit the expression of IRF-1 (Ohmori and Hamilton, 1997).  
The ability to activate transcription of target genes through binding specific 
promoters is the most important activity of IRF-1.  The IRF-1 binding sequence is 
identified to be 5’-G(A)AAA(G/C)(T/C)GAAA(G/C)(T/C)-3’, which is contained in 
the promoters of many ISGs.  On the molecular level, IRF-1 can be considered as a 
typical modular molecule of which the distinct protein domains mediate different 
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molecular actions.  Similar to other IRF-family members, the DNA-binding domain 
(DBD) is mapped to the 125 amino acids at the N-terminal of IRF-1 protein.  As 
mentioned before, this DBD is characterized to be a HTH motif with five tryptophan 
repeats.  Indeed, as revealed by the crystal structure of IRF-1 bound to PRDI DNA 
element in the IFN-β promoter, this HTH motif of IRF1 exemplifies the HTH motif of 
IRF family which binds DNA through three of the five conserved tryptophans 
(Escalante et al., 1998). 
Interestingly, by activating the IRF-2 promoter, IRF-1 also induces the 
expression and accumulation of IRF-2 which can inhibit the transcription of 
IRF-1-inducible genes (Harada et al., 1994).  Through this negative feedback loop, 
IRF-1 and its antagonist IRF-2 have been identified as regulators of type I IFN and 
type I IFN-inducible genes.  Moreover, mRNA levels of both IRF-1 and IRF-2 are 
found to be regulated by cell cycle through an unclear mechanism.  The reciprocal 
regulation between IRF-1 and IRF-2 has been shown to have impact on tumor 
progression.  Harada et al. overexpressed IRF-2 in NIH 3T3 cells and injected some 
of the IRF-2-overexpressing cell clones subcutaneously into nude mice.  After 2 to 3 
weeks, tumors emerged in those mice and continued to grow vigorously, but no 
tumors developed in mice injected with untreated NIH 3T3 cells.  The tumorigenic 
activity of IRF-2 was suppressed after increasing the expression of IRF-1 in the same 
clones by cotransfection of another plasmid carrying IRF-1 gene.  It was also 
suggested in their study that a transient decrease of the IRF-2/IRF-1 ratio might be a 
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key point in the regulation of cell growth by IFNs (Harada et al., 1993). 
Some IRF-1-induced transcriptions require the interaction of IRF-1 with other 
transcription factors.  IRF-1 can regulate the expression of inducible nitric oxide 
synthase (iNOS), and in macrophages, the induction of iNOS can catalyze the reaction 
of transient production of nitric oxide (NO) which is one of the contributors of 
macrophage cytotoxicity to tumor cells.  The production of NO is induced by the 
interaction between IRF-1 and NF-κB through the iNOS promoter, to defend against 
bacterial infection and to facilitate the elimination of tumor cells.  The iNOS 
promoter can also be activated by combined action of IFN-γ with IRF-1 or NF-κB.  
In addition, it has been reported that IRF-1 can cooperate with p53, the tumor 
suppressor, to induce the transcription of p21WAF/CIP1, an important regulator of 
cell cycle progression (Tanaka et al., 1996).  It can also form a protein complex with 
some histone acetylases, CREB binding protein (CBP) for instance. 
The activity of IRF-1 is regulated through many different ways by various 
factors.  Phosphorylation, a common way to regulate many transcription factors, is 
one of the best studied regulations of IRF-1.  Bioinformatic and biochemical analysis 
showed that the IRF-1 protein can be phosphorylated on serine/threonine at multiple 
sites, but whether IRF-1 requires phosphorylation to fulfill its function is still 
unknown.  The oncogenic transcription factor IRF-2 can prevent certain promoters 
from being activated by IRF-1, possibly through competing with IRF-1 to bind to the 
same DNA-binding site.  IRF-8, another functional antagonist of IRF-1, has the 
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ability to suppress the IRF-1 induced activation of ISRE-associated genes.  The 
inhibitory activity of IRF-8 on IRF-1 is modulated on two key levels: one is that 
IRF-8 is expressed specifically in lymphoid, whereas IRF-1 is extensively expressed; 
the other is when certain tyrosines of IRF-8 are phosphorylated, its DNA-binding 
activity but not its association with IRF-1 is inhibited, thus it facilitates 
heterodimerization of IRF-8 and IRF-1 and also enhances DNA binding of the whole 
complex (Sharf et al., 1997).  
Detailed studies suggest that IRF-1 plays a role in host defense against 
pathogens, tumor suppression, and development of the immune system by inducing 
downstream genes involved in immunomodulation, antiviral effects, and antitumor 
effects.  It has been shown that the overexpression of IRF-1 in different cell types 
from mammalian species resulted in growth inhibition (Mario Koster, 1995).  IRF-1 
can act as a tumor suppressor.  The role of IRF-1 in tumor suppression and immune 
response can be described from several aspects.  One of the important events during 
DNA damage induced apoptosis of mitogen-activated T lymphocytes is the 
production of Fas ligand which binds to Fas receptor on cell membrane to induce 
apoptosis by initiating a series of signal transduction.  In addition, Fas/FasL system 
also plays a role in the apoptosis of cytotoxic T-cell targeted cells.  Studies 
employing different methodologies, including deletion and mutagenesis of an IRF-1 
binding site in FasL promoter, overexpression of IRF-1, and down-regulation of IRF-1 
activity by antisense RNA, suggest that the FasL expression in activated T cells is 
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regulated by IRF-1 (Chow et al., 2000). Moreover, some members of the caspase 
family, such as caspase-1 and caspase-7, were investigated to be transcriptionally 
induced by IRF-1.  The caspase family is an essential component in the signaling 
pathways to induce apoptosis.  Cytokine is another inducer of apoptosis, and IRF-1 
seems to be an important mediator in initiation of apoptosis by certain cytokines.  
IFN-γ, for example, can induce cell cycle arrest and p53-independent apoptosis in 
primary cultured hepatocytes, however, hepatocytes from IRF-1-deficient mice were 
completely resistant to IFN-γ-induced apoptosis.  It was proposed that IRF-1 
mediates the IFN-γ signaling in primary hepatocytes, regulating cell cycle arrest via 
p53 expression and apoptosis (Kano et al., 1999).  Northern blot analysis showed 
that IFN-γ-induced p53 mRNA expression but not constitutive p53 mRNA expression 
was regulated by IRF-1.  Furthermore, gene expression profiling demonstrated that 
except for a few detectable amount of caspase-1 in IRF-1 deficient mice, Fas, 
caspase-3, or caspase-11 did not change in between wild type and IRF-1-deficient 
hepatocytes. 
As mentioned previously, IL-12 is a key cytokine in linking innate and 
acquired immune responses, allowing phagocytes to facilitate the development of 
cell-mediated immunity to a variety of pathogens as well as tumor cells.  IL-12 has 
been characterized for its ability to induce IFN-γ secretion from T cells and NK cells 
directly.  To elucidate the potential ability of IRF family members in the regulation 
of IL-12, IL-12 mRNA and protein levels in LPS and/or IFN-γ-activated macrophages 
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from IRF-1-/- and IRF-2-/- mice were examined.  Results from this study indicate that 
loss of IRF-1 leads to impaired production of not only IL-12 p40 but also IL-12 p35 
mRNA after treatment with LPS or LPS plus IFN-γ (Salkowski et al., 1999).  
Therefore, not only does IRF-1 have the properties to repress tumor growth, but also 
has the function to facilitate immune response to fight against tumors.  
3.4. IRF-3 
Another member in IRF family, IRF-3, also plays a critical role in regulation 
of innate immunity and has potential activities in regulating macrophages to kill 
tumor cells.  Unlike IRF-1 whose production is induced by viral infection and 
cytokines, IRF-3 is constitutively expressed in the cells.  Recent studies have 
identified that IRF-3 is a key regulator of type I IFN genes with its active form 
induced by pathogens (Alexopoulou et al., 2001).  IRF-3 is initially found 
accumulated in the cytoplasm with an inactive form.  ISG15 is an IFN-induced 
ubiquitin-like protein which can interfere with ubiquitin-mediated degradation of 
IRF-3, thus stabilize IRF-3 in the cells (Okumura et al., 2008).  Upon stimulation by 
LPS, dsRNA or viral infection, IRF-3 is post-translationally activated by TLR 
signaling, and after being phosphorylated on serine/threonine, it forms a complex with 
CBP/p300.  Then, this complex translocates into the nucleus and activates the 
transcription of IFN-α/β, as well as other ISGs.  
Structural and functional analyses have revealed that phosphorylation-induced 
IRF-3 dimerization generates an extensive acidic pocket with responsibility for 
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binding with CBP/p300.  Based on the crystal structure of C-terminal regulatory 
domain of IRF-3 (residues 175−427), named as IRF-3 175C, and mutational analyses 
of IRF-3, it was proposed that the phosphorylation-induced dimerization is the 
activation mechanism of IRF-3 (Takahasi et al., 2003).  Ser385 or Ser386 (2S site) is 
a part of the unique phosphorylation site of the Ser-Ser-Leu motif (SSL motif) in 
IRF-3 gene.  Mutagenesis of the serine residue in the 2S site to alanine abolished the 
phosphorylation and dimerization of IRF-3.  Meanwhile, an observation showed that 
mutation of the serine and threonine residues between residues 395 and 407, termed 
as 5ST site, to phosphomimetic aspartate (IRF-3 5D) can result in constitutively active 
IRF-3 (Lin et al., 1999).  This super active IRF-3 is a strong activator of promoters 
containing ISRE regulatory elements or PRDI-PRDIII.  This observation supported 
an autoinhibition model proposed by Hiscott et al. that two regions of IRF-3, 
corresponding to residues 380−427 (serine-rich region) and 98−240, are interactional 
to form a closed structure in an inactive state that is opened by the introduction of 
massive negative charges by multiple phosphorylation. 
Besides the stimulation of IRF-3 by TLR, IRF-3 and its targeted IFN genes 
can also be activated by bacteria like Listeria monocytogenes through a TLR- and 
Nod2-independent pathway.  Scientists in Max F. Perutz’s Laboratory investigated 
the signals and molecules associated with the synthesis of IFN, and also the response 
to IFN by mouse macrophages infected with Listeria monocytogenes.  They 
observed that the synthesis of type I IFNs, expression of a subset of IFN-induced 
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genes, and the biological response to type I IFNs were lost upon IFN-β deficiency.  
Based on these observations, they demonstrated that IFN-β is the critical 
immediate-early IFNs made during infection.  And they further identified that the 
induction of IFN-β is absolutely dependent on the presence of IRF-3 (Stockinger et al., 
2004).  
From the studies on the mechanisms of the pathogen induced innate antiviral 
response, scientists found that these responses are almost all lead to the activation of 
IRF-3 and IRF-7.  As mentioned above, the TLR is essential in the induction of 
IRF-3 and IRF-7.  Double-stranded RNA can be recognized by TLR-3 or 
cytoplasmic helicases retinoid-inducible gene-1 (RIG-1) and melanoma 
differentiation-associated gene-5 (MDA-5) which are characterized by the presence of 
caspase recruitment domains (Rego et al., 2001) (Kato et al., 2006).  The 
downstream signaling pathways of TLR-3 or RIG-1/MDA-5 lead to the 
phosphorylation of IRF-3 by two kinases: TBK-1 and IKKε.  The key residue of 
phosphorylation is serine 386 at the C-terminal region.  Alternative pathway 
mediated by TLR-4 can also lead to the phosphorylation of IRF-3, wherein TLR-4 
triggers the myeloid differentiation primary response gene 88 (MyD88)-independent, 
TIR-domain-containing adaptor-inducing IFN-β (TRIF)-dependent pathway via 
TRIF-related adaptor molecule (TRAM) to induce type I IFNs.  TRAF-6, RIP-1 and 
TRIF can trigger the phosphorylation of IRF-3 by TBK-1 and IKKi, resulting in the 
translocation of IRF-3 to the nucleus where it induces the expression of IFN-β and 
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IFN-inducible genes.   
After phosphorylation, IRF-3 then homodimerizes or heterodimerizes with 
IRF-7, another important interferon regulatory factor largely restricted to lymphoid 
tissue, and translocates to nucleus where it associates with the CRFB binding protein 
CBP/p300 (Lin et al., 1998).  Notably, the activation of IRF-3 alone is sufficient to 
induce type I IFNs and initiate the type I IFNs-associated immune responses.   
3.5. IRF-7 
At first, IRF-7 was considered as a factor binding to the Qp promoter of the 
Epsin-Barr Virus (EBV) based on previous studies (Pagano, 1997).  Thereafter, it 
was identified that a splice variant of IRF-7 was a critical factor in the induction of 
IFN-α genes (Au et al., 1998).  It shares most of IRF-3 activities and is activated in 
an IRF-3 dependent pathway. 
Not only type I IFNs but also TNF-α can activate the expression of IRF-7, 
which can be observed in plasmacytoid dendritic cells where the production of TNF-α 
is high due to TLR-7/-8 and TLR-9 action.  Gene knockout study has clearly showed 
the important function of IRF-7.  Kenya Honda et al. used mice deficient in the 
IRF-7 gene to show the essential role of IRF-7 in the induction of IFN-α/β (Honda et 
al., 2005).  They generated IRF7-/- mice and then collected mouse embryonic 
fibroblasts (MEFs) from three distinct viruses infected IRF7-/- mice.  As revealed by 
quantitative RT-PCR, IFN-α/β mRNA was markedly reduced in IRF7-/- mice.  In 
contrast, MEFs from MyD88-/- mice retained the ability to induce IFN-α/β mRNAs in 
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response to virus infection.  The study clearly showed that IRF-7 is essential for the 
activation of type I IFNs via two different pathways: virus-activated, 
MyD88-independent pathway and the TLR-activated, MyD88-dependent pathway.  
It also demonstrated that a decreased serum IFN levels was correlated with IRF-7, 
indicating the importance of the IRF-7-dependent induction of systemic IFN 
responses for innate antiviral immunity.  Also, IRF-7 is activated in its 
phosphorylated form and the key residues for phosphorylation of IRF-7 by 
TBK-1/IKKε are serine 477 and 479.  However, TLR-7 and TLR-9 stimulated 
phosphorylation of IRF-7 depends on MyD88 and IĸB. 
IRF-3 and IRF-7 are early IRFs, among the nine mammalian IRFs, activated 
by TLR and other types of signal factors that play a very important role in the initial 
induction of type I IFNs.  Previous studies also showed that the complex of IRF-3 
homodimer and coactivator CBP/p300 is responsible for the primary activation of 
IFN-α/β gene.  Then, the secreted IFN-α/β subsequently induces IRF-7 expression, 
which has a role in the secondary amplification of IFN-α/β gene expression in a 
phosphorylation-dependent manner (Honda and Taniguchi, 2006).  It is noteworthy 
that the C-terminal regulatory domain RD and serine-rich region (SRR) are conserved 
between IRF-3 and IRF-7 and these proteins share functional similarity (Takahasi et 
al., 2003).  
3.6. Other members of IRF family 
Besides the members of IRF family discussed above in details, other members 
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are also very important in the immune system.  The IRF family plays a role in 
directing the development of innate and adaptive immunity, which can be 
demonstrated by the activity of IRF-4 and IRF-8 (Eisenbeis et al., 1995) (Politis et al., 
1992).  Both of them are only expressed in immune cells.  They can not only bind 
the common binding site of the IRF family, ISRE, but also bind various Ets/IRF 
composite elements through their interaction with PU.1.  Due to the activity of IRF-8, 
the production of IFNs is much higher in dendritic cells than in other cells. 
IRF-5 plays a role in the induction of type I IFNs as well as proinflammatory 
cytokine production.  It can be activated by TLR signaling.  For example, TLR-4 
can trigger the MyD88-dependent pathway which induces the formation of a complex 
that consists of TRAF-6, IL-1-receptor-associated kinases (IRAKs) and IRF-5.  The 
complex can further lead to the activation and translocation of NF-κB, AP-1 and 
IRF-5, resulting in the production of proinflammatory cytokines.  Like IRF-3 and 
IRF-7, IRF-5 can be phosphorylated by TBK1/IKKε, but this phosphorylation only 
can not lead to its activation.  It is also reported that IRF-5 has a role in apoptosis 
and the immune response to pathogens.  Another member IRF-6 is a vital regulator 
in determining the keratinocyte proliferation-differentiation switch (Richardson et al., 
2006). 
Following type I IFN-receptor interaction, a latent cytoplasmic IRF-9 complex 
with STAT1 and STAT2 through the activation of the JAK/STAT pathway, binds to the 
ISRE, and stimulates transcription of a large set of IFN-stimulated genes.  The 
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STAT1, STAT2 and IRF-9 complex is thought to be a typical type I IFN transcription 
factor, nevertheless, it is identified that it is also involved in the IFN-γ signaling 
pathway (Matsumoto et al., 1999).  
The IRF family members play critical multifunctional roles throughout the 
immune system.  They are involved in various signaling pathways, and some of the 
members are potent mediators regulating the antitumoral immune responses.  It 
holds a great promising to the anti-cancer strategies by targeting on IRF family 
members.   
4. Adenoviral vectors 
Gene therapy is a promising tool to treat or prevent diseases.  Based on the 
cargo gene to be delivered, gene therapy can be largely categorized into three types: 
(1) replacing a mutated gene that causes disease with a healthy copy, (2) inactivating a 
mutated gene that is functioning improperly, and (3) introducing a new gene into the 
body to help fighting a disease. 
Another focus of gene therapy studies, besides ‘cargos’, is the vectors to 
deliver those cargos into targeted tissue.  Indeed, vector design and safety issues, 
such as insertional mutagenesis and host immune responses to gene delivery systems 
have become the major focus of the area of gene therapy (Romano, 2007).  There are 
several established gene-delivery systems among which the virus-mediated systems 
are the most effective and widely studied.   
Adenoviral vectors, second only to retroviruses, are among the most 
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commonly used viral vectors because of their certain advantages over other vectors, 
such as high transduction efficiency, ability to transduce a broad range of target cells, 
capacity to package large sequences up to ~7.5kb, high levels of short-term 
expression, and stability of recombinant vectors.  Moreover, they can deliver genes 
to both dividing and non-dividing cells.  The most extensively used recombinant 
adenoviruses (Ads) are generated from human Ads of serotypes 2 and 5. 
Adenoviruses are non-enveloped icosahedrons with the outer structure 
comprised of 240 hexons and 12 pentons at vertices of the icosahedral particle.  A 
trimeric glycoprotein fiber projects from each penton terminating with a granular head.  
A molecule on the host cell surface named coxsackie and adenovirus receptor (CAR) 
can bind to the distal granular head of the fiber, and thus can initiate the receptor 
mediated endocytosis of adenovirus.  During the process of endocytosis, besides the 
interaction of fiber-CAR, adenoviral penton base also interacts with the alpha-v 
subunit of a heterodimerized cell-surface receptor (composed of alpha-v and integrin 
beta-1 subunits) by RGD motif to assist the endocytosis.  After entering into the cell 
cytoplasm, virus core escapes from the endosome and migrates towards the nucleus 
where the double-stranded viral DNA is released from the degraded capsid and enters 
into the nucleus through the nuclear pore.  Interestingly, unlike many other viruses, 
the viral DNA replicates and is transcribed in the host cell nucleus, but is actively 
prevented from integrating into the host genome, which makes adenoviral vector an 
ideal choice for preventing ‘insertional mutation’. 
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The adenoviral genome (Figure 1-4) is a linear double-stranded DNA about 
30 to 38 kb consisting of two overlapping regions termed Early (E) genes and Late (L) 
genes.  The genome is flanked by an inverted terminal repeats on each end.  E1 
gene is required for the activation of transcription of all the early genes, therefore the 
viral proteins can be significantly inhibited by disrupting E1 gene.  Currently, the 
E1-deleted Ad vector is being used as vaccine carrier.  Deletion of both E1 and E3 
genes can free up to 7.5kb for cloning gene of interest.  E1- and E3-deleted Ad 
vector is now available in many commercial kits and is widely used in gene therapy.  
Although significant progress has been made in adenovirus mediated gene therapy for 
cancer, great effort still needs to be taken to further reduce vector toxicity and 
increasing gene transfer efficacy.  
 
Figure 1-4.  Genome of adenovirus and adenoviral vector.  Adenoviral genes 
are shown in green.  Gene deleted in adenoviral vector are shown in dotted lines.  
Gene and promoter introduced into adenoviral vector are shown in red. 
A major problem caused by Adenovirus-mediated gene therapy is the 
immunogenicity of adenovirus.  Methods such as chemical or genetic modifications 
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on the recombinant adenoviruses have been explored to reduce this immunogenicity.  
Chemical modifications have been made on fibers, penton bases, and hexon capsids of 
adenovirus by covalently attached polymers to effectively reduce its toxicity and 
immunogenicity.  Among those methods, modification of the fiber knobs with 
PEGylated RGD is the most widely used.  
Great progress has been made in Ads-mediated gene therapy by developing 
helper-dependent adenoviral vectors (HDVs) in which all viral coding genes are 
deleted.  In both small and large animal models, HDVs can significantly reduce the 
chronic toxicity related to the early generation of adenoviral vectors after systemic 
administration (Seiler et al., 2007).  
Targeted delivery presents another major challenge.  The diffusion of 
adenoviral vectors has been suggested as the major safety issue in Ad-mediated gene 
therapy through local administration.  Adenoviral vectors administrated into the 
desired site in the body often diffuse away to other tissues and organ systems.  Again, 
modification on adenovirus is a promising way to develop targeted adenovirus vectors.  
Scientists are seeking better ways to modify vectors without affecting their infectivity.  
A new strategy for targeted adenovirus-gene delivery system, which takes advantage 
of the extremely tight interaction between avidin/streptavidin and its ligand biotin, 
was created in 2002 by Mark W. Pandori et al. (Pandori et al., 2002).  They 
covalently conjugated biotin moieties to adenoviral vectors and coated silica 
microbeads with streptavidin.  Biotinylated viral particles were stably and tightly 
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immobilized on the solid surface, which virtually avoided the diffusion of adenovirus 
into the solution.  In addition, they observed a marked increase in transduction 
efficiency for target cells.  
Since adenoviruses do not tend to integrate into the host genome, recombinant 
adenoviral vectors have been very popular in cancer immunotherapy.  A recent study 
on IFN-γ gene transfer using adenovirus found a distinct difference in gene expression 
profiles after IFN-γ treatment on skin lesions from 19 patients with cutaneous 
lymphoma (CL).  Among the 495 differentially expressed genes, 251 genes 
expressions were up regulated with a gene signature of induced type I and type II 
IFNs, and the other 244 genes expressions were down regulated.  Their study also 
provided evidence in support of the positive role of vector induced innate response in 
tumor regression (Urosevic et al., 2007).  
In addition, adenoviral vectors are also an effective way to deliver small 
interfering RNA to the target cells.  The adenovirus-based siRNA gene transfer is 
also a potential strategy for effective cancer treatment.  It has been demonstrated that 
siRNA technology combined with Ad-mediated gene transfer is a promising approach 
to silence gene expression in tumor cells for gene therapy or gene function studies.  
Adenovirus-delivered HIF-1α-targeted siRNA can remarkably reduce the expression 
of HIF-1α which leads to the enhanced hypoxia-mediated tumor cell apoptosis.  In 
addition, intratumoral injection of adenovirus-delivered HIF-1α-targeted siRNA had 
significant negative effects on tumor growth (Zhang et al., 2004).  
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5. Macrophage and cancer therapy 
The dual role and plasticity of macrophages in the tumor tissue made it a 
promising target for cancer gene therapy and immunotherapy where various ways are 
sought to overcome immune silencing effects of the tumor microenvironment, thus 
restore the antitumor activity of macrophages as well as the whole immune system. 
As early as in 1974, Fidler by the first time applied ex vivo-activated 
macrophages infusion to suppress pulmonary metastases in mice with B16 melanoma 
(Fidler, 1974).  In human cancer treatment, monocytes have been isolated from the 
cancer patients’ blood, and then matured by M-CSF and activated with LPS or IFN-γ 
ex vivo.  After that, the activated macrophages were infused back into the patients, 
but there was no clinical positive response to support that those macrophages have 
antitumor activity (Andreesen et al., 1998).  Alternatively, it is reported that 
macrophages ex vivo transfected by recombinant adenovirus with antitumor genes 
such as IFN-γ and M-CSF had increased antigen-presenting activity and cytotoxicity, 
resulting in increased antitumor potential (Lei et al., 2000).  Moreover, the 
administration of autologous-derived macrophage activated killer (MAK) cells has 
gained much progress in cancer immunotherapy (Ritchie et al., 2007).  The tolerance 
and activity of human autologous IFN-γ-activated macrophages have been assessed in 
some pilot clinical trials in cancer patients.  
On the other hand, in combination with the possible antitumor activities of 
IRFs, the constitutively active forms of IRF-3 and IRF-7 have been delivered by 
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adenoviral vectors into primary human macrophages to test their potential roles in 
activating macrophages (Romieu-Mourez et al., 2006).  It was reported that 
Ad-IRF-7-transduced macrophage exerted cytotoxic activities on cancer cells, and the 
active form of IRF-7 could lead to novel antitumor effector functions.  
In the present study, a novel macrophage-targeted, particulate-mediated gene 
delivery system (Figure 1-5) was designed aiming to modulate the activation status of 
the targeted macrophage cells for cancer therapy.  This system is to use zymosan 
particles conjugated with recombinant adenoviruses encoding different interferon 
regulatory factor (IRF) family genes, specifically IRF1, IRF3, and IRF7.  We 
hypothesized that the intracellular expression of IRF gene in macrophage cell line 
could lead to the activation of NF-κB, which in turn induces some important 
inflammatory cytokines downstream of NF-κB signal transduction pathway, resulting 
in the macrophages’ antitumor activities.  
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Figure 1-5.  Scheme of macrophage-targeted, particulate-mediated adenoviral 
gene delivery system.  Top-left: recombinant adenovirus carrying an IRF gene.  
Top-right: biotinylated adenovirus.  Bottom-left: streptavidin-coated zymosan.  
Bottom-right: streptavidin-coated zymosan conjugated with biotinylated adenovirus.  
Note: molecules and viruses are not drawn to scale. 
The tumors can polarize macrophage into non-immune response state which 
usually shut down the NF-κB pathway.  NF-κB is the key mediator in a variety of 
pathways initiated by bacterial products, viruses, as well as tumor cells.  In the 
NF-κB network, IRFs also play important roles, and it can also regulate IFNs 
expression.  And the expression of IFNs is also a feature of antitumoral macrophages.  
Taking together, as we hypothesized, intercellular increasing of IRF family genes 
could be an effective way to turn on the NF-κB-mediated pathways which could result 
in the activation of immune responsible macrophages.   
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Additionally, this novel strategy used zymosan to modify the adenoviral 
vectors through a very strong non-covalent biological interaction between biotin and 
streptavidin.  The adenovirus-zymosan particles delivery system has several 
advantages over adenovirus-only or adenovirus-conjugated microbeads system.  
Firstly, adenoviral techniques are designed to achieve high efficiency gene delivery, 
and zymosan can be targeted by macrophages.  The adenovirus-conjugated zymosan 
particles can be large enough targeted by macrophages only.  We designed these 
novel vectors to achieve effectively targeted delivery of interested genes.  Secondly, 
magnetic beads can result in the cell death, usually after two days incubation, while 
zymosan is bio-degradable in macrophages.   
In the following chapter, detailed procedures and techniques of this study will 
be included, from construction of recombinant adenoviral vectors to packaging 
recombinant viruses, and from infection of macrophage cell line to the assay tests.  
There are two main objectives in this study: to test (1) if or not the new designed 
technique is good for targeted delivery of genes into macrophages; (2) if or not the 
intracellular delivery of IRFs can result in the production of desired cytokines or other 
effector molecules.  
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CHAPTER TWO 
 
MATERIALS AND METHODS 
 
1. Construction of adenoviral vectors 
1.1. Acquisition of wildtype IRF and EGFP genes 
Coding sequences (CDSs) for wildtype interferon regulatory factors (IRFs) 
were obtained from Invivogen (San Diego, CA) in expression vectors pUNO-mIRF1, 
pUNO-mIRF3 and pUNO-mIRF7, which were shipped as transformed and 
lyophilized E.coli (strain GT116).  The lyophilized E.coli was resuspended and 
grown on Fast-Media Blas (LB agar supplemented with blasticidin) following the 
manufacture’s protocol.  Ten colonies of E.coli containing each gene were isolated 
and seeded in 3ml of Fast-Media Blas liquid medium and shaken at 37°C for 
overnight.  Plasmid was prepared from each culture using QIAprep-mini kit. 
As a control gene, enhanced green fluorescent protein (EGFP) was used to 
substitute mIRF1 gene fragment in the pUNO-mIRF1 vector.  The EGFP gene was 
first amplified by PCR from pIRES2-EGFP (Clontech) to introduce EcoRV restriction 
sites on both ends, and then ligated into pCR2.1-topo vector to generate 
pCR2.1-EGFP.  The EcoRV fragment of pCR2.1-EGFP containing EGFP CDS was 
ligated to pUNO backbone which was generated from pUNO-mIRF1 vector by 
AgeI/NheI (New England Biolab, NEB)-digestion to remove mIRF1 CDS, 
gel-purification and blunting using Klenow fragment (NEB), resulting in 
pUNO-EGFP.  
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1.2. Construction of entry vectors 
The expression cassettes on pUNO plasmids containing EF-1α promoter, 
HTLV 5’ untranslated region (UTR), CDS of IRFs or EGFP and SV40 
polyadenylation signal were transferred to pENTR4 vector (Invitrogen) by restriction 
enzyme-digestion and ligation to create Entry clones. 
The restriction enzymes used for subcloning of each gene are listed in Table 
2-1. 
Gene Enzymes to cut inserts on pUNO vector 
Enzymes to cut 
pENTR4 vector Blunted? 
pUNO-mIRF1 NotI and SwaI EcoRI Yes 
pUNO-mIRF3 SwaI and XhoI EcoRV and SalI No 
pUNO-mIRF7 SwaI and XhoI EcoRV and SalI No 
pUNO-EGFP SwaI and XhoI EcoRV and SalI No 
Table 2-1.  Restriction enzymes used in cloning IRF and EGFP genes into Entry 
vectors.  As indicated above, if the ends generated by the enzymes are not 
compatible with the ends of the digested Entry vector, the insert and the vector was 
blunted by Klenow fragment (NEB) or by Quick Blunting Kit (NEB).  The digested 
and blunted pENTR4 vector was dephosphorylated by Antarctic phosphatase (NEB) 
before ligation.  Ligation products were transformed to Top10 chemically competent 
cells which were plated on LB agar plates supplemented with Kanamycin for 
overnight growth at 37oC.  Colonies were picked for each gene and were inoculated 
into media culture.  Plasmids were extracted using Miniprep kit (Qiagen) and cut 
with appropriate enzymes to check the correct clones.  The correct plasmids (entry 
clones) were then proceeded to the LR recombination reaction with pAD/PL-DEST 
vector. 
1.3. Mutagenesis to generate superactive IRF3 and IRF7 
Mutagenesis was performed using FINNZYMES Phusion site-directed 
mutagenesis kit (product code F-541).   
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The primers were designed according to the type of desired mutations 
following the kit instruction.  The point mutation of mIRF3 gene was generated by 
designing a mismatch in the mutagenic primer.  According to the kit instruction, the 
desired mutation was in the middle of the primer flanked by 10-15 perfectly matched 
nucleotides on each side.  The deletion of mIRF7 was created by designing primers 
that border the deleted region on both sides and perfectly match the template.  In 
both cases the primers were phosphorylated at 5’ end for subsequent ligation.  Tms 
were calculated using the nearest-neighbor-method-based calculator on Finnzymes’ 
website (www.finnzymes.com). 
For ‘super activated’ mIRF3-Mut3 which contains S396D mutation, 
PrimerMut31 (5’p-ctcccttaccgatgaccagtacaag, bolded letters denotes the introduced 
point mutation) and PrimerMut32 (5’p-ataggctggctgttggagatg) were used to amplify 
the whole plasmid following the manufacture’s instruction. 
Similarly, PrimerMut71 (5’p-gtatgcaaggcatacctggagg) and PrimerMut72 
(5’p-ctcggtgagagctggctgtt) were used to amplify the whole plasmid to generate 
truncated IRF7 (lacking residues 238~410). 
3μl (about 25ng) of PCR product from mutagenesis reaction was used to 
proceed with ligation step in a 10μl ligation reaction using 0.5ul of Quick T4 DNA 
ligase (NEB).  Ligation products were then transformed into one-shot Top10 cells. 
 Mutated plasmids were verified by sequencing. 
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1.4. Construction of adenoviral vectors 
The expression cassettes in pENTR4 vector flanked by recombination sites 
attL1 and attL2 were shuttled to adenoviral vector pAd/PL-DEST (Invitrogen) by LR 
recombination according to the product manual. 
After the recombination reaction, 5μl of reaction mix was transformed into 
one vial of the TOP10 competent cells.  The transformed cells were plated on the LB 
agar medium supplemented with Ampicillin and incubated in 37°C incubator 
overnight. 
Four colonies of each plate were picked, dotted gently onto the 
chloramphenicol LB plates and transferred into Ampicillin LB liquid medium.  The 
plates and liquid culture were incubated in 37°C incubator overnight.  The correct 
plasmids should not grow on the chloramphenicol LB plates due to the lost of CAMR 
gene between attR1 and attR2 sites during LR recombination.  The resultant 
plasmids were extracted using Miniprep kit (Qiagen). 
2. Production and purification of adenoviral particles 
Adenoviral particles were produced in packaging cell line AD293 (Clontech) 
by transfection of linearized adenoviral plasmid DNA.  AD293 cell line, a derivative 
of the commonly used HEK293 cell line (human embryonic kidney cells transformed 
by sheared adenovirus type 5 DNA), has improved cell adherence and plaque 
formation properties.  AD293 cells produce the adenovirus E1 gene in-trans, 
allowing the production of infectious viral particles when the cells are transfected 
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with E1-deleted adenovirus.  
2.1. Transfection and preparation of initial viral stock 
AD293 cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM, Invitrogen, CA) supplemented with 10% fetal bovine serum (BSA), 100 
units/ml penicillin and 100 μg/ml streptomycin, at 37°C and 5% CO2. 
Before transfection into AD293 cells, the adenoviral vectors were digested by 
PacI to expose the left and right viral inverted terminal repeats (ITRs) which allows 
proper viral replication and packaging.  
 Transfection was performed using LipofectamineTM 2000 following the 
protocol provided by Invitrogen.  Briefly, the day before transfection, AD293 cells of 
>90% confluency in one T75 flask were trypsinized, counted and plated into 6-well 
plate with 5×105 cells/well in 2ml medium.  On the day of transfection, the culture 
media were replaced with 1.5ml of OpitMEM I Medium containing serum but no 
antibiotics. 
For each construct, ~2μg linearized adenoviral vector DNA was used for each 
transfection.  The linearized adenoviral vector DNA was diluted in 250μl of 
Opti-MEM I medium without serum and mixed gently.  Then 6μl of Lipofectamine 
2000 was diluted in 250μl of Opti-MEM Medium without serum, mixed gently, and 
incubated for 5 minutes at room temperature (RT).  After 5 minutes incubation, the 
diluted DNA and the diluted LipofectamineTM 2000 were combined together and 
mixed gently.  The mixture was then incubated at room temperature for 20 minutes, 
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allowing the DNA-Lipofectamine 2000 complexes to form.  Each 
DNA-LipofectamineTM 2000 complex was added dropwise to each well in 6-well 
plate and mixed well by shaking the plate back and forth.  The transfected cells were 
incubated overnight at 37°C in a 5% CO2 incubator.  
The medium containing the complex was removed and replaced with complete 
culture medium the next day after transfection.  On the third day (48 hours post 
transfection), the cells were trypsinized and transferred to a sterile 10cm tissue culture 
plate containing 10ml of complete culture medium.  The culture media were changed 
every 2-3 days if needed until visible regions of cytopathic effect (CPE) were 
observed.  Then the culture media were maintained or replenished to allow the 
infections to proceed until 80% CPE were observed.  The adenovirus-containing 
cells were harvested and transferred into sterile capped tubes.  The harvested cells 
were be stored in -80°C or made into crude viral lysate directly. 
For preparing a crude viral lysate, the harvest cells together with the medium 
were centrifuged at 300g for 5 minutes.  The supernatant (usually 5ml of supernatant 
was left for resuspending the cell pellets) was transferred to a new sterile capped tube 
and stored in -80°C.  The cell pellets were resuspended in the remaining medium. 
The resuspended cells were freezed on dry-ice-acetone bath and then thawed 
in 37°C water bath.  The freeze-thaw cycle was repeated for 4-5 times.  After the 
last thaw step, the lysed cell cultures were centrifuged at 3,000rpm for 15 minutes.  
The supernatant was collected in a new capped tube and labeled as cell lysate. 
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2.2. Verification of transgene by Western Blot 
The productions of IRF proteins in AD293 cells were examined by Western 
Blotting.  The protocol is described briefly as follows. 
2.2.1. Preparing cell lysates from 6-well plates 
The cell culture media were removed and the cells were washed once with 
ice-cold PBS.  After aspirating PBS, 200µl 1×ice-cold lysis buffer supplemented 
with appropriate amount of protease inhibitor was added to each well.  The plate was 
incubated on a shaker for 10min.  The lysed cells in each well were transferred to a 
1.5ml microcentrifuge tube and gently pipetted up and down by using a 1cc syringe 
and 23-gauge needle to shear the genomic DNA.  Then the tubes were incubated on 
ice for 20min and centrifuged at 14,000rpm for 10min at 4oC.  The supernatants (cell 
lysates) were transferred to new tubes and stored at -20oC for future use.  The protein 
concentrations were measured by the Bradford Assay. 
2.2.2. PAGE and Western blotting 
According to the protein concentration, up to 30µl lysate (ddH2O was used to 
dilute samples when necessary) was added into a 1.5ml tube.  The same amount of 
positive control was used and 30µl of 2× lamini buffer was added to each sample and 
control tube.  15µl of prestained protein marker (NEB) was used each time.  The 
samples, controls, and marker were denatured in boiling water for 5min and then 
chilled on ice.  
50μl of each sample or control was loaded in each lane of 4-15% SDS-PAGE 
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gel.  The running condition was set at 100V (constant voltage) for 1hr 30min.  The 
running buffer was 1×TGS.  The proteins were transferred to nitrocellulose 
membrane after running in 1×transferring buffer at 100V for 50min.  
After membrane-transfer, the membrane was blocked in 15ml 5% milk/TBST 
on shaker for one hour at room temperature.  The membrane was washed 3 times 
(5min each) with TBST.  Then the membrane was incubated in primary antibody 
diluted with 10ml 5% BSA/TBST (dilution range was 1:500~1:1000) on the shaker at 
4oC overnight.  The next day, the membrane was washed 3 times (5min each) with 
TBST and incubated in horse radish peroxidase (HRP)-conjugated secondary antibody 
(diluted with 10ml 5% milk/TBST) on the shaker at room temperature for 4~6hr, after 
which the membrane was washed 5 times (5min each) with TBST.   
The membrane was then transferred into a clean dish and soaked in 10ml 
enhanced chemiluminescent Western blotting detection reagents for 1min and 
immediately used for film exposure and development.  The exposure time was 
usually 30s~10min. 
2.3. Viral particle amplification 
Amplification of adenoviral particles was done by infecting AD293 cells with 
initial viral stock.  The day before infection, the cells (>90% confluent in T75 flask) 
were trypsinized, counted and plated at the density of 3×106 cells per 10cm plate in 
10ml complete growth medium.  On the day of infection, the cells were verified at 
80~90% confluency, and then were infected by 1ml of crude viral lysate.  The 
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infected cells were incubated at 37°C in a CO2 incubator until 80~90% of the cells 
rounded up or loosely attached to the tissue plates (4-5days post infection).  
The cells were harvested and made into lysate by using the same procedure as 
described above.  To make the desired amount of adenoviruses, the following 
amplification procedures were performed. 
Second round amplification:  The adenovirus of each type was amplified by 
using the lysate from 10cm dish culture to infect one T75 flask of AD293 cells. 
Third round amplification:  The adenovirus of each type was amplified by 
using the lysate from T75 flask to infect eight T150 flasks of AD293 cells.  
2.4. Viral particle purification 
ViraBind Adenovirus Purification Kit (Cell Biolabs) was used to purify viral 
particles.  Before purification, the lysate from eight T150 flasks of infected AD293 
cells was thawed in 37°C water bath and passed through a 0.45μm sterile filter to 
remove cell debris.  Then the viral lysate was purified by following the purification 
protocol as shown in Figure 2-1.  Briefly, the viral lysate was passed through 
0.45μm filter first before purification.  The purification filter was pre-rinsed with 
wash buffer.  Due to the limitation of the capacity of the filter, half of the lysate was 
passed through purification filter first followed by the steps as shown in the 
flow-chart.  After filter regeneration, the other half of the lysate was purified by 
following the same procedure.  
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Figure 2-1.  Flow-chart of viral particle purification. 
2.5. Viral particle concentration 
The eluate (containing purified virual particles in elution buffer) from the last 
step was then concentrated by using 100,000MWCO Vivaspin 20 centrifugal 
concentrator (Vivoscience).  The eluate was applied into Millipore tube and 
centrifuged at 3500×g for 15~20min until the desired volume was achieved. 
2.6. Buffer exchange 
After concentration, the buffer used to suspend viral particles was changed to 
PBS.  The buffer exchange step was done by using 5ml ZedaTM Desalt Spin 
Columns (Pierce) according to the manufacturer’s protocol.  Briefly, a new column, 
with the bottom closure twisted off and cap loosened, was placed into a 15ml conical 
collection tube.  Then the column was centrifuged at 1,000×g for 2min to remove 
57 
storage solution.  Then 2.5ml of buffer for exchange (PBS) was added to the column 
and the column was centrifuged at 1,000×g for a minute to remove buffer.  This step 
was repeated for three times after which the column was placed into a new collection 
tube.  The sample (concentrated eluate) was loaded to the center of the compact resin 
bed.  To ensure maximal protein recovery, a stacker (100μl) of PBS was applied to 
the resin bed after the sample was fully absorbed.  
After buffer exchange, the virus/PBS solution was passed through a 0.2μm 
filter and stored in -80°C for future use. 
2.7. Determination of viral titers. 
The viral infectivity of the purified, concentrated, and buffer-exchanged 
recombinant viral samples were measured by using QuickTiterTM Adenovirus Titer 
Immunoassay Kit (Cell Biolabs, CA).  
 AD293 cells were harvested and resuspended in culture medium at the 
density of 2.5×105 cells/ml.  1ml of the cell culture was seeded in each well of a 
24-well plate.  The plate was incubated at 37°C, 5% CO2 for 1 hour. 
During the 1hr incubation, the serial dilutions of the five samples were 
prepared by a series of 1:100 and 1:10 dilution as shown in Figure 2-2. 
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2μl original 
viral sample
198μl 
medium
20μl
180μl 
medium
20μl
180μl 
medium
180μl 
medium
10-410-310-2 10-7  
Figure 2-2.  Scheme of serial dilution of viral stock. 
After one hour incubation, the cells were infected by 100μl of the diluted 
samples and one well of cells were “infected” by 100μl of medium as a negative 
control.  The plate was incubated at 37°C, 5% CO2 for 2 days.  
 After two days incubation, the immunostaining step was performed by 
following the kit protocol as shown in Figure 2-3.  
Remove 
medium
Add 0.5ml/well cold 
methanol
Incubate 20mins,
-20°C
Wash with PBS
3 times×5mins/each
Add 1% BSA/PBS, 
incubate 1hr, RT
Aspirate BSA, add 0.25ml/ml 1st
antibody, incubate 1hr, RT
Wash with PBS  
3 times×5mins/each
Add 0.25ml/well 2nd antibody, 
incubate 1hr, RT
Wash with PBS
5 times×5mins/each
Add 0.25ml/well 1×DAB, 
incubate 10mins, RT
Aspirate DAB, wash with 
PBS, 2 times
Add 1ml/well PBS, 
count brown cells, 
calculate viral titer
 
Figure 2-3.  Flow-chart of titer determination. 
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3. Biotinylation and conjugation of viral particles 
3.1. Biotinylation 
The biotinylation reagent used in this study was NHS-LC-LC-Biotin in 
water-free DMSO at a concentration of 50mg/ml (Pierce).  5μl of Biotinylation 
reagent (diluted in DMSO to 3mg/ml) was added into 200μl adenoviral stock (~107 
viral-particles/200μl) and mixed well.  The mixture was incubated on ice for 2 hours.  
The residual biotinylation reagent was removed by spin chromatography at 
14,000rpm on a 2ml Zeda Desalt Spin Column (Pierce).  This step was repeated 3~4 
times by adding proper amount of PBS and spinning down.  Finally, 100~200μl of 
PBS was added to the column to resuspend the biotinylated viral particles in a total 
volume of 300μl. 
3.2. Conjugation with zymosan 
The yeast fraction Zymosan A (purchased from Sigma, product number: 
Z4250) was conjugated to streptavidin using protocol previously developed by the Yu 
Lab (see Appendix B).   
Streptavidin-Zymosan pellets are kept in Hepes-buffered saline (HBS) after 
preparation.  Before use, the buffer was changed to PBS by centrifugation.  3μl of 
Streptavidin-Zymosan/PBS was added to each of the biotinylated adenovirus solution 
and mixed well. The mixture was incubated on an orbital shaker at room temperature 
for 1hr, after which the mixture was centrifuged at 14,000rpm for 2min.  The 
supernatant was discarded and the adenovirus-zymosan particles were resuspended in 
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200μl PBS.  
4. Infections and functional assays of macrophages 
RAW-Blue cell line (purchased from Invivogen, San Diego, CA) is a mouse 
macrophage reporter cell line derived from RAW264.7 macrophage.  RAW-Blue 
cells are stably transfected with an expression cassette that produces the secreted 
embryonic alkaline phosphatase gene (SEAP) under the control of transcription 
factors NF-κB and AP-1.  In this study, the activity of NF-κB and AP-1 can be 
measured by a colorimetric alkaline phosphatase assay QUANTI-Blue.  
4.1. Infection of RAW-blue reporter cells 
The day before infection, the RAW-Blue cells were seeded in 6-well plate at 
the density of 5×105cells per well in 2ml complete medium (DMEM supplemented 
with 10% BSA, 100 units/ml penicillin and 100 μg/ml streptomycin) supplemented 
with 200μl/ml Zeocin.  On the day of infection, the medium was changed to DMEM 
without phenol red (D1145, Sigma).  Then, 100μl of each adenovirus-zymosan/PBS 
sample was added dropwise to one well.  Each sample was done in duplicates.  The 
cells were incubated at 37°C in a CO2 incubator for two days.  The supernatants 
were collected and the cells were prepared into lysate.  
4.2. QUANTI-Blue assay 
The QUANTI-Blue kit (purchased from Invivogen, San Diego, CA) is a 
colorimetric enzyme assay specifically to determine the activity of SEAP in the 
supernatants of cell cultures.  In the presence of SEAP, the QUANTI-Blue medium 
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turns purple-blue, which in turn indicates the activity of NF-κB and AP1.  The assay 
was done by following the kit protocol.  
One bag of Quanti-blue mix was dissolved in 100ml ddH2O and passed 
through a 0.22μm filter.  200μl of Quanti-blue reagent was added to each well in a 
96-well plate, and then 5μl cell supernatant of each sample was added to the reagent.  
The plate was incubated at 37oC for 1~24hr.  The SEAP activity was assessed by 
reading the OD at 655nm with a microplate reader (Bio-rad).  
4.3. Nitric oxide quantification 
The total nitrate/nitrite concentrations of the cell supernatants were determined 
by using the Nitric Oxide Quantitation Kit (Active Motif, CA).  The nitrate assay 
and/or nitrite assay were done by following the kit protocol.   
Nitrate assay:  The standard, blank, and sample wells were prepared by 
adding the reagents or samples as shown in Table 2-2. 
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Well 
Nitrate Standard 
200μM NaNO3 (μl)
Samples (μl) 1×Assay Buffer (μl) 
A1 0 - 70 
B1 5 - 65 
C1 10 - 60 
D1 15 - 55 
E1 20 - 50 
F1 25 - 45 
G1 30 - 40 
H1 35 - 35 
Blanks - - 70 
Samples - 70 - 
Table 2-2.  Sample preparation in nitrate assay. 
20μl reconstituted cofactors solution (one vial of lyophilized cofactor was 
dissolved in 1.2ml ice-cold ddH2O) was added to each well.  10μl reconstituted 
nitrate reductase solution (one vial of lyophilized nitrate reductase was dissolved in 
0.6ml ice-cold 1×assay buffer) was added to each well.  The plate was placed on a 
rocking platform to mix the solutions at 150rpm for one minute then incubated at RT 
in the dark for 30min. 
After the incubation, 50μl Griess reagent A was added to each well followed 
by immediately adding 50μl Griess reagent B to each well.  The plate was incubated 
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for another 20min at room temperature to allow the color to develop.  The 
absorbance was read on a spectrophotometer at 540nm with a reference wavelength of 
655nm.  
Nitrite assay:  The standard, blank, and sample wells were prepared by 
adding reagents or samples as in Table 2-3. 
Well 
Nitrate Standard 
200μM NaNO2 (μl)
Samples (μl) 1×Assay Buffer (μl) 
A1 0 - 100 
B1 5 - 95 
C1 10 - 90 
D1 15 - 85 
E1 20 - 80 
F1 25 - 75 
G1 30 - 70 
H1 35 - 65 
Blanks - - 100 
Samples - 100 - 
Table 2-3.  Sample preparation for nitrite assay. 
50μl Griess reagent A was added to each well, and 50μl Griess reagent B was 
added immediately afterwards.  The color was developed for 10min at room 
temperature.  The absorbance was read on a spectrophotometer at 540nm with a 
reference wavelength of 655nm.  
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The standard curves were generated by plotting the absorbance values versus 
nitrate or nitrite concentrations.  The total NO production of a sample was calculated 
by nitrate standard curve, and the endogenous nitrite concentration was calculated by 
nitrite standard curve. 
4.4. Western blotting:  
Phosphorylated p65 protein in RAW-Blue cells was analyzed by Western 
Blotting.  The protocol was similar to the one described in Section 2.2, except that 
phosphatase inhibitor was added in cell lysate. 
4.5. Cytokine array: 
The cytokine productions in the culture supernatants were analyzed by using 
Proteosome Profiler TM Array-Mouse cytokine array panel A array kit (purchased 
from R&D System).  
Briefly, 2.0ml of Array Buffer 6 was pipetted into each well of the 4-well 
multi-dish.  The membranes were placed into each well with the identification 
numbers facing upward.  For the blocking step, the dish was incubated at room 
temperature on a rocking platform for one hour.  During the blocking, samples were 
prepared by adding 800μl of culture supernatants, 200μl of Array Buffer 5, and 0.5ml 
of Array Buffer 4 in separate tubes.  Then 15μl of detection antibody cocktail was 
added to each tube.  The samples were mixed and incubated at room temperature for 
one hour.  Array Buffer 6 was aspirated from the wells after one hour incubation and 
the samples were added into each well.  The dish was incubated overnight at 2~8°C 
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on a rocking platform.  
The membranes were removed into 4 individual plastic containers with 20ml 
of 1×Wash Buffer.  The dish was rinsed with ddH2O and dried thoroughly.  The 
membranes were washed for three times, 10min each wash, on a rocking platform.  
The streptavidin-HRP solution was diluted in Array Buffer 5 and 1.5ml of the diluted 
streptavidin-HRP was added into each well of the dish.  The membranes were 
returned to the dish containing streptavidin-HRP and incubated at room temperature 
for 30min on a rocking platform.  After the incubation, the membranes were washed 
as described above followed by the incubation with ECL.  The membranes were 
placed on the same plastic sheet protector and covered with plastic wrap, and then 
exposed to X-ray film for 1-10min.  
The positive signals on the film were identified by laying the transparency 
template from the kit over the image.  The three pairs of positive control spots were 
provided as position-setting spots.  The data were quantified by scanning the film on 
a transmission-mode scanner and analyzing the array image using software ImageJ. 
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CHAPTER THREE 
 
RESULTS 
 
1. Construction of recombinant adenoviral vectors 
The strategy used to construct adenoviral vectors expressing mIRF1, mIRF3 
and mIRF7 are outlined in Figure 3-1.  The expression cassettes containing the 
hEF1-HLTV hybrid promoter, the coding sequence of a desired IRF gene, and the 
SV40 polyadenylation signal were excised from pUNO vectors and ligated into 
pENTR4 backbone through sticky-end or blunt-end ligations (Table 2-1), resulting in 
Entry clones.  Entry clones were then recombined with promoterless adenoviral 
destination vector pAD/PL-DEST through LR-recombination to generate destination 
clones. 
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Figure 3-1.  Construction of adenoviral vector (using mIRF1 as an example).  
Bacterial expression elements are shown in yellow; bacterial replication origins are 
shown in pink; recombination sites are shown in purple; mammalian promoters are 
shown in green; mammalian polyadenylation sequences are shown in light blue; 
selection markers are shown in orange; adenoviral elements are shown in navy blue. 
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The lengths and directions of inserts in entry clones were checked by 
restriction-enzyme digestions (Figure 3-2A).  As shown in Figure 3-2B and Figure 
3-2C, multiple clones for each gene showed correct restriction fragment patterns.  
One of these correct clones for each gene was picked for LR recombination.   
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Figure 3-2.  Restriction-enzyme digestions of pENTR4-mIRF1, -mIRF3 and 
–mIRF7.  (A) Selection of restriction enzymes for pENTR4-IRF1.  (B) and (C) 
Restriction-enzyme digestion of mIRF1 (B), mIRF3 and mIRF7 (C).   
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 To construct control adenoviral vector expressing EGFP, coding sequence for 
EGFP was first PCR-amplified from pIRES2-EGFP vector and then cloned into 
pCR2.1-TOPO vector.  EcoRV digestion of the resulted clones showed that one of 
these clones has the correct insert (Figure 3-3A).  The EcoRV fragment was then 
used to substitute mIRF1 CDS in pUNO-mIRF1 to generate pUNO-EGFP.  The 
expression cassette of pUNO-EGFP was again cloned into pENTR4 and transferred 
into pAD/PL-DEST through LR-recombination.  The correctness of pUNO-EGFP 
and pENTR4-EGFP was also checked by diagnostic restriction-enzyme digestion 
(Figure 3-3B, Figure 3-3C). 
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Figure 3-3.  Restriction-enzyme digestions of pCR2.1-EGFP (A), pUNO-EGFP 
(B) and pENTR4-EGFP (C).  Correct clones are indicated by arrows on the top of 
the images. 
2. Mutagenesis 
The super-active IRF3 (Mut3) was generated by substitution of Ser396 with 
Asp, with corresponding DNA sequence changed from TCT to GAT.  The 
super-active IRF7 (Mut7) was generated by deletion of amino acid residues 238-410.  
Mutagenesis was performed at the level of Entry vector using whole-plasmid PCR 
strategy.  Sequencing of resultant plasmids (Figure 3-4) showed that desired 
mutation and deletion was correctly introduced.   
72 
 
Figure 3-4.  Construction strategies and sequencing results of super-active 
mutants of mIRF3 (A) and mIRF7 (B). 
3. Verification of transgene expressions by Western blotting 
The expression vectors pAD/PL-DEST containing mIRF or EGFP genes was 
linearized by PacI-digestion to expose viral ITRs flanking the vector dsDNA on both 
sides.  The linear dsDNA were transfected into AD293 cells to initiate viral 
replication and transgene expression.  The expressions of transgenes in AD293 cell 
crude lysate and supernatant were examined by Western Blotting (Figure 3-5).  All 
mIRF1, mIRF3, mIRFmut3, mIRF7 and mIRFmut7 can be readily detected.  
Unexpectedly, although the transgenic proteins should only be produced in the cells 
and not secreted in the supernatant, the mIRF1 protein can also be detected in 
supernatant, which might be due to cell death or other reasons. 
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Figure 3-5.  Detection of transgene expression in AD293 cell by Western 
blotting.  (A) mIRF1. (B) mIRF3 and Mut3. (C) mIRF7 and Mut7.  Lanes for cell 
lysate and supernatant are labeled on the top of the figures in light blue or red text.  
Size markers are shown in red and the band for 47.5kD is labeled. 
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4. Adenoviral titer 
To assess the infectivity of the recombinant viral particles, the titer of 
adenoviral stocks were measured after purification, concentration and buffer exchange. 
The calculated titers were shown in Table 3-1.  Due to some unidentified reasons, 
the titer of Ad-Mut7 was still undetectable, and the titers for Ad-mIRF1 and Ad-Mut3 
are much lower than the other three.   
 Ad-EGFP Ad-mIRF1 Ad-mIRF3 Ad-Mut3 Ad-mIRF7 
Titer 
(IFU/ml) 
1.2×1010 1.8×108 3.4×1011 1.3×108 2.5×1010 
Table 3-1.  Recombinant adenovirus titer. 
5. Expression of transgenes in macrophage cell line transduced with 
adenovirus-conjugated zymosan particles  
The adenovirus-zymosan conjugates were made according to the procedures 
described in Section 3 of Chapter 2.  RAW-Blue cells were infected in vitro with 
adenovirus-zymosan conjugates at a MOI of ~10PFU/cell.  Two wells of a 6-well 
plate were transduced with a same viral stock as duplicate.  The same amount of 
fresh medium was added to two wells as negative control.  24hr and 48hr after 
infection, the macrophages transfected with zymosan-Ad-EGFP conjugates were 
examined under fluorescent microscope to observe the expression of reporter gene 
EGFP.  As shown in Figure 3-6, after 48hr infection, nearly 100% transduction 
efficiency was observed.   
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Figure 3-6.  RAW-Blue macrophage cells transfected with zymosan-Ad-EGFP 
conjugates express EGFP gene.  Fluorescent microscopic pictures were taken at 
48hr after infection. 
After verifying the expression of EGFP, the culture supernatants and cell 
lysates were collected separately for the functional assays.  In summery, totally 24 
samples (lysate and supernatant) from the 12 experimental wells (2 replica for each 
treatment or control), were collected.   
6. Effects of NF-κB activation in adenovirus-zymosan conjugate-transduced 
RAW-Blue cells 
The activation of NF-κB was analyzed by a colorimetric reporter assay 
(QUAITI-Blue assay) as indicated in Section 4.2 of Chapter 2.  The RAW-Blue 
cells are engineered to carry a stably-integrated expression cassette to produce 
secreted embryonic alkaline phosphatase (SEAP) under the control 
NF-κB/AP-1-inducible promoter.  Thus, the SEAP activity in culture supernatant 
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reflects the intracellular activity of NF-κB.  The QUANTI-Blue medium changes to 
a purple-blue color in the presence of SEAP.  To test whether NF-κB could be 
activated in the macrophages by transfected genes, 5μl of transfected or untreated 
macrophage culture supernatant was subjected to QUAITI-Blue assay where the 
SEAP activity was measured (Figure 3-7).  Compared with blank wells and 
untreated cell samples, color change caused by the SEAP activity was readily 
observed in all the transfected cell culture supernatants (Figure 3-7A).  
Quantitatively, the OD655nm values of cell treated by adenovirus-zymosan conjugate 
were 3~8-fold higher than the blank and untreated ones, suggesting NF-κB activation 
in transfected cells.   
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Figure 3-7.  In vitro effects of adenovirus-conjugated zymosan particles on the 
activation of NF-κB.  (A) QUANTI-Blue assay for the detection and quantification 
of SEAP in culture supernatant.  In the presence of SEAP, the medium changes to a 
purple-blue color.  (B) Quantification (OD655nm) of (A).  Blank: fresh medium 
only; UT: untreated cells (i.e. supernatant of cells treated with medium). RAW-Blue 
cells were seeded in 6-well dishes at 5×105 cells/2ml each well. The next day, they 
were infected with the adenovirus-zymosan particles at the indicated MOI 
(~10PFU/cell). The supernatants were collected from duplicate wells after 48hr. The 
activation of NF-κB was assessed by measuring the level of SEAP by QUABTI-Blue 
assay. Blank: fresh medium only; UT: untreated cells (i.e. supernatant of cells treated 
with medium). 
 
 
 
78 
7. Total nitric oxide production in culture supernatants of adenovirus-zymosan 
conjugate-transduced RAW-Blue cells 
Nitric oxide (NO) is a key effector molecule associated with the tumoricidal 
activity of activated macrophages.  To determine the possible production of this 
cytotoxic molecules in the transfected cells, the NO production in each sample was 
measured.  Interestingly, the NO productions in the IRF-transfected samples were 
even lower than EGFP-transfected cells, and all the transfected samples had even 
lower NO productions than untreated ones.  As indicated in Figure 3-8, a significant 
increase of the NO production in the treated cells was not observed.  However, the 
result is not conclusive, as a lot of studies showed that NO production is unstable and 
also hard to reflect the real amount in the cell cultures (See Chapter 3).   
 
Figure 3-8.  In vitro effects of adenovirus-conjugated zymosan particles on the 
NO production.  RAW-Blue cells were seeded in 6-well dishes at 5×105 cells/2ml 
each well. The next day, they were infected with the adenovirus-zymosan particles at 
the indicated MOI (~10PFU/cell). The supernatants were collected from duplicate 
wells after 48hr. The NO production was measured by NO quantification kit. Blank: 
kit reagent only; UT: untreated cells (i.e. supernatant of cells treated with medium). 
79 
8. In vitro effects of adenovirus-zymosan conjugates on cytokine production in 
transduced macrophage cell line.   
As an important mediator between innate and adaptive immunity, the activated 
macrophages can produce a variety of effector molecules, among which cytokines 
have critical roles in conferring the antitumor activity of macrophages.  The 
cytokines secreted in the cell culture supernatant can also reflect the possible 
activations of some related signaling pathways.  In order to determine whether the 
treated macrophages can produce M1-like cytokines, a cytokine array was used to 
detect the expressions of a series of cytokines (Figure 3-9). 
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Figure 3-9.  In vitro effects of adenovirus-conjugated zymosan particles on the 
cytokine productions.  (A) Cytokine array images scanned from X-ray films. The 
films were exposed for 10min. The cytokines were captured by spotted antibodies on 
the membranes in duplicates. The cytokine types were indicated in the colored 
squares.  Note: the red squares are for positioning; the blue ones indicate the 
possible M1-like cytokines; the purple ones are possible M2-like cytokines; the 
yellow ones indicate untypical cytokines for M1/M2. (B) Quantification of (A). 
RAW-Blue cells were seeded in 6-well dishes at 5×105 cells/2ml each well. The next 
day, they were infected with the adenovirus-zymosan particles at the indicated MOI 
(~10PFU/cell).  The supernatants were collected from duplicate wells after 48hr. 
The cytokines secreted in the supernatants were detected by Mouse Cytokine Array 
Panel A Array. Blank: fresh medium only; UT: untreated cells (i.e. supernatant of 
cells treated with medium). Refer to the appendix for the cytokine abbreviations. 
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 As Figure 3-9A and Figure 3-9B indicated, increased production of certain 
cytokines was observed in the treated cells.  However, compared with Ad-EGFP 
transfected cells, there were no significant increase of cytokine productions in the 
Ad-IRF-transfected cells.  Some M1-like cytokines (indicated by blue squares in 
Figure 3-9A and Figure 3-9B) possibly downstream of TLR/NF-κB pathway were 
induced or up-regulated.  One of the M2-like cytokine, IL-1ra, was also observed in 
the treated cells but not in untreated cells.  The G-CSF and sICAM-1 are not found 
to be typical markers of M1 or M2, but they could be involved in inflammation.  
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CHAPTER FOUR 
 
DISCUSSION 
 
Macrophages are indispensable for competent immune defense against 
pathogens as well as malignant cells.  Besides their ability to directly eliminate 
invaders by phagocytosis, they can also secrete a wide variety of effector molecules 
resulting in multiple functions, including tumoricidal activity.  The gene expression 
patterns and functions of macrophages are greatly influenced by the 
microenvironmental signals.  Macrophages are highly plastic.  As demonstrated by 
previous works, TAMs can be ‘re-educated’ by tumor environment which can 
markedly suppress their antitumor activities.  Functions of macrophages are 
regulated within a functional spectrum with M1 and M2 being the two extremes, 
where the TAMs are more M2-polarized.  Pharmacological skewing of TAM 
polarization from an M2–like phenotype to a full M1 phenotype has been shown to 
sustain antitumor immunity (Sica et al., 2008).  As more evidences are becoming 
available for the molecular mechanisms regulating the switch from M2 to M1, 
targeting on TAMs polarization and reprogramming them to restore their antitumor 
activities are a promising strategy for cancer treatment.   
Although the mechanisms underlying macrophage polarization remain largely 
unknown, the defective activation of NF-ĸB-mediated pathway seems to play an 
important role.  IRF family members are critical mediators in the NF-ĸB signaling 
network, regulating the productions of IFNs and ISGs. 
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To test the idea of reactivating TAMs towards M1 phenotypes, we designed 
this novel zymosan-adenovirus delivery system and did the pilot experiments.   
We have shown firstly that the adenovirus-zymosan conjugates achieved 
nearly 100% transduction efficiency.  It is documented that the 
solid-phase-conjugated adenoviral vectors have certain functional advantages over 
free viruses in the solution (Pandori et al., 2002).  In the present study, the 
adenovirus-zymosan delivery system further supported the above notion in terms of 
transduction efficiency.  Although we have not tested the side effects elicited by 
zymosan and/or adenovirus, the present system could be an effective method to 
transfer therapeutic genes into target cells, especially for localized delivery into 
macrophages.   
On the other hand, according to the preliminary data in our study, adenovirus 
and zymosan undoubtedly serve as the first-level executors of macrophage activation.  
It is known that zymosan can bind to TLR2 (Krishnan et al., 2007) which could 
possibly lead to the activation of NF-κB and production of proinflammatory cytokines.  
However, it is also reported that zymosan can not activate NF-κB in the rat liver 
macrophages, but does activate activator protein-1 (AP-1) both in rat liver 
macrophages and in the U937 human monocytic cell line (Tran-Thi et al., 1995) 
(Pierce et al., 1996).  
Although the mechanisms by which the cells recognize dsDNA viruses remain 
largely unknown, it has been found that dsDNA viruses, such as adenovirus, can 
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activate antigen-presenting cells (APC) via TLR-independent activation of IRF3 
(Nociari et al., 2007).  Furthermore, studies showed that adenovirus can initiate a 
cascade of signaling transduction upon interaction with TLR9 (Barton, 2007).  
One of the observations in our experiments is that RAW-Blue macrophage cell 
line transfected by IRF genes mediated via adenovirus-zymosan conjugates had 
increased production of NF-κB-AP-1-inducible SEAP, which indicates the activation 
of NF-κB/AP-1 pathway in the transduced macrophages.  Defective activation of 
NF-κB is frequently observed in the TAMs isolated from established solid tumors 
(Sica et al., 2000).  Re-activate NF-κB or NF-κB-mediated signaling pathway could 
be an effective way to induce production of a wide spectrum of proinflammatory 
cytokines.  The current results from QUANTI-Blue assay were not definitive in 
explaining whether the effect is elicited by IRF genes, since the expression of SEAP 
was also up-regulated in the Zymosan-Ad-EGFP transduced macrophages.  Another 
observation is, compared with the effect caused by IRF3 and Mut3 on SEAP 
production, the super active IRF3 (Mut3) seems to be more effective in activating 
macrophages.  More experiments with different conditions (especially different 
MOIs and different time points) are needed to further validate this result.  As we 
were unable to detect phosphorylated NF-κB-p65 in our samples using Western 
blotting, the activation of NF-κB still needs to be analyzed by other methods or with 
more protein loading.  It is also possible that the NF-κB has been activated, but the 
p65 subunit was not phosphorylated as the p65 phosphorylation has not been proved 
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to be a required event for the transcriptional activity of NF-κB.  Moreover, we were 
trying to detect the phosphorylated p65 on Ser276, but the phosphorylation could be 
on other sites.   
Another observation in our study is that the NO productions did not increase 
in those treated cells as expected, but on the contrary, the total NO level in the 
untreated cells was higher than in the treated ones.  It is possible that the production 
of NO in the infected macrophages is a rapid process, and the NO has been volatilized 
after 48hr incubation.  But for the untreated cells, the NO production measured 
should reflect a stable status.  It has been demonstrated in a lot of studies that NO 
production is very unstable and the circumstances required for its release from 
macrophages are controversial.  The NO production by macrophages can vary 
greatly along with different cell types, incubation times and species (Albina, 1995).  
Additionally, even if there is NO production, it does not necessarily indicate the 
increased activities of macrophages in fighting against invaders (Vazquez-Torres et al., 
1995).   
The secretion of a variety of proinflammatory cytokines is an important 
characteristic for M1-polarized competent immune responses, including antitumor 
effects.  The cytokines are critical indicators for evaluating the activity and polarity 
of macrophages.  We have shown in this study that transfected macrophages 
generally had increased production of M1-like cytokines.  According to the studies 
summarized in (Sica and Bronte, 2007), many of the up-regulated cytokines in our 
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study are molecules downstream of NF-κB, including TNF-α, KC, CCL2-CCL5, 
MIP-2 and CXCL10.  These cytokines could also be induced by IRF genes directly 
or by IRF-induced interferons through autocrine and paracrine signaling.  
Interestingly, the increased production of M2-like cytokine, such as IL-1ra, was also 
observed in the transfected macrophages except the IRF3-transfected macrophages.     
Granulocyte colony-stimulating factor (G-CSF) is different from GM-CSF or 
M-CSF which has been reported to be potent M1- or M2-polarizing signal, 
respectively (Fleetwood et al., 2007).  G-CSF is considered to be an important factor 
in regulating neutrophil numbers and activities during inflammation (Lieschke et al., 
1994).  Soluble ICAM-1 (sICAM-1) is a member of Ig gene family and can mediate 
cell-cell contact in different situations (Springer, 1990).  Although there is no direct 
evidence showing the role of sICAM-1 in enhancing M1-like phenotypes, it has been 
suggested that sICAM-1 could enhance the recruitment of neutrophils and increase 
expression levels of TNF-α and MIP-2 in lungs (Schmal et al., 1998).  Both of 
G-CSF and sICAM-1 are normally at very low level in circulation, but the levels can 
increase markedly under stress conditions, such as infection (Hamilton, 2008), 
(Schmal et al., 1998).  In line with this notion, our study showed that there is no 
detectable G-CSF and sICAM-1 in the untreated cells.  The up-regulation of 
sICAM-1 and G-CSF in our treated cells could have a positive effect on macrophages 
in the recruitment of ‘supporting forces’, i.e. other phagocytes, especially neutrophils.   
As mentioned above, the zymosan particles and adenoviruses can interact with 
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TLR receptors leading to proinflammatory responses, the production and/or 
up-regulation of certain cytokines could come from three sources: the effect elicited 
by the binding of zymosan to the TLR2; the effect from the cells sensing viral dsDNA 
through TLR9-dependent and/or –independent pathways; and the effects directly from 
the expression of the transfected IRF genes. 
Moreover, there could be some other cytokines secreted in our samples, but 
their levels were below the detection sensitivity of the cytokine array used in this 
study.  We plan to use methods with higher sensitivity to have a more detailed 
analysis of the secreted cytokines in future studies.  
These pilot experiments in the present study shed lights on this novel 
adenovirus-zymosan conjugate-mediated delivery system as a potential way to 
transfer therapeutic genes.  Further studies are needed to modify the parameters of 
the system, including adenovirus/zymosan ratio, MOI, incubation time, etc.  It is also 
necessary to do more experiment to confirm the results, for example, use nuclear 
extract to do Western blotting because nuclear translocation is an important step in 
NF-κB activation.  Additionally, future works also include in vitro and in vivo 
transduce our candidate genes into mouse primary macrophages to further test their 
possible antitumor activities.  Different combinations of the recombinant 
adenoviruses containing the IRF genes will be co-transduced into the macrophages to 
test the effects on macrophage activation.  Finally, it is of great importance to 
evaluate the safety of the delivery system, especially the negative effects elicited by 
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zymosan particles and adenoviruses. 
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Appendix A  Abbreviations 
 A 
Ads: adenoviruses 
ATF: activating transcription factor 
 C 
CAR: coxsackie and adenovirus receptor 
CARD: caspase recruitment domain 
CBP: CREB binding protein 
CCL: CC chemokine ligand 
CL: cutaneous lymphoma 
CML: chronic myelogenous leukemia 
CREB: cAMP response element-binding protein 
CSF: colony stimulating factor 
CXCL: CXC chemokine ligand 
 D 
DBD: DNA binding domain 
 E 
ECM: extracellular matrix 
EMAP: endothelial monocyte activating peptide  
ERK: extracellular signal-regulated kinase 
 G 
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GCSF: G-CSF, granulocyte colony-stimulating factor 
GM-CSF: Granulocyte-macrophage colony-stimulating factor 
 H 
HDV: helper-dependent adenoviral vector 
HIF: hypoxia-inducible factor 
HMG: high mobility group protein  
HTH motif: helix-turn-helix motif 
 I 
IAD: IRF association domain 
ICAM: intercellular adhesion molecule 
IFN: interferon 
IFNAR: Interferon-Alpha Receptor 
IFNGR: Interferon-Gamma Receptor 
IFNLR: Interferon-Lambda Receptor 
 IL: interleukin 
 IL10R2: Interleukin 10 Receptor Chain 2 
 iNOS: inducible nitric oxide synthase  
 IRAK: IL-1-receptor-associated kinase 
IRF: interferon regulatory factor 
 ISGs: interferon-stimulated genes 
ISRE: IFN-stimulated response element 
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 J 
JAK: Janus kinase 
 K 
KC: CXCL1, CXC chemokine ligand 1 
 L 
LPS: lipopolysaccharide  
 M 
MAK: macrophage activated killer 
MAPK: mitogen-activated protein kinase 
MCP: macrophage chemoattractant protein 
M-CSF: macrophage colony-stimulating factor 
MDA-5: melanoma differentiation-associated gene-5 
MDF: macrophage-derived chemotactic factor 
MEF: mouse embryonic fibroblast 
MHC: major histocompatibility complex 
MIP-2: CXCL2, CXC chemokine ligand 2 
MKP: MAPK phosphatase 
MMP: matrix metalloproteinase 
MMPI: synthetic MMP inhibitor 
MyD88: myeloid differentiation primary response gene 88 
 N 
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NK cells: natural killer cells 
NLS: nuclear localization signals 
NO: nitric oxide 
 P 
PAI: plasminogen activator inhibitor 
PBM: peripheral blood monocytes(s) 
PGE2: prostaglandin E2 
PM: peritoneal macrophage(s) 
PML: promyelocytic leukemia 
PRDI: positive regulatory domain I element 
 R 
RIG-1: retinoid-inducible gene-1  
 S 
sICAM-1: soluble intercellular adhesion molecule-1 
SRR: serine-rich region 
SSL motif: Ser-Ser-Leu motif 
STAT protein: signal transducers and activators of transcription protein 
 T 
TAM: tumor-associated macrophage 
TDCF: tumor-derived chemotactic factor 
TGF: transforming growth factor 
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TIR: Toll/IL-1 receptor domain 
TLR: toll-like receptor 
TNF: tumor necrosis factor 
TRAF-6: TNF receptor-associated factor 6 
TRAM: TRIF-related adaptor molecule 
TRIF: TIR-domain-containing adapter-inducing IFN-β 
TSP 1: thrombospondin 1 
 V 
VEGF: vascular endothelial growth factor 
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Appendix B  Protocol for preparation of streptavidin-zymosan 
Derivatization of ADH-Zymosan with SPDP: 
1. Suspend 10mg ADH-Zymosan in 1ml PBS 
2. Add 5μl SPDP solution (final conc. = 100μM) 
3. Incubate with shaking for 2 hr, RT 
4. Spin at 1000 × g for 5min, carefully suck off fluid and resuspend pellet in 1ml PBS 
5. Repeat step 4 twice 
6. Finally resuspend pellet in 1ml PBS 
Derivatization of Streptavidin with SPDP: 
1. Dissolve 1mg Streptavidin in 0.2ml PBS 
2. Add 1.25μl SPDP solution, mix well (final conc. = 250μM, molar ratio 
SPDP:streptavidin ~2.5) 
3. Incubate for 2hr, RT 
4. Remove residual reagent by spin chromatography on a 2ml Zeba Desalt Spin 
Column (Pierce) equilibrated with PBS according to manufacturer’s instructions 
Zymosan Streptavidin Conjugation: 
1. To 1ml of SPDP-modified Zymosan (see above) add 10μl 1M DTT (final conc. = 
10mM) (prepare freshly!) 
2. Incubate with shaking for 30min, RT 
3. Spin at 1000 × g for 5min, carefully suck off fluid and resuspend pellet in 1ml PBS 
4. Repeat step 4 three times 
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5. Finally resuspend pellet in 1ml PBS 
6. Immediately add 50μl (~ 250μg) of SPDP-modified streptavidin (see above) 
7. Incubate with shaking o.n., RT 
8. Spin at 1000 × g for 5min; carefully suck off fluid and resuspend pellet in 1ml HBS 
9. Repeat step 8 twice 
10. Finally resuspend pellet in 1ml HBS 
Remarks: 
SPDP-modification of Zymosan will create ~108 protected sulfhydryl groups per 
Zymosan particle, whereas SPDP-modification of streptavidin will create ~1 protected 
sulfhydryl group per molecule.  Altogether, the given protocol will yield conjugates 
with ~106 streptavidin molecules per Zymosan particle. 
Buffers & Reagents: 
1. ADH-Zymosan: prepared as described 
2. SPDP-Solution: 20mM (6.25mg/ml) SPDP (Sigma) in water-free DMSO; store in 
tightly sealed tube at – 20° C for no more than 4 weeks 
 
Protocol: G. Schwamberger   last modified: 24-05-07 
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